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SYNTHESIS AND BIOLOGICAL EVALUATION OF SMALL 
MOLECULAR DRUG CANDIDATES FOR THE TREATMENT OF 
HER2 OVEREXPRESSED BREAST CANCER 
ANRAN ZHAO 
ABSTRACT 
In the US breast cancer is the most common cancer after skin cancer. Currently in 
the US the average risk of a woman to develop breast cancer in her life is roughly 12%. 
About 25-30% of breast cancer patients have HER2 overexpressed tumor, and the growth 
of tumor cell is depend on HER2 pathway. It has been well-documented that patients with 
over-expressed HER2 are associated with increased disease recurrence, worse prognosis 
and lower survival. Currently there are two type of HER2 targeting drug. The first group 
is HER2 monoclonal antibody drugs such as trastuzumab approved by FDA in 1998; the 
second type is intracellular tyrosine kinase inhibitors such as lapatinib approved by FDA 
in 2007. Presently trastuzumab is one of the most efficient in clinic for HER2 
over-expressed breast cancer patients, however many patients didn’t gain benefit due to 
the de novo or acquire resistance. The resistance of trastuzumab involves multiple 
cellular pathway, research indicates that HSP27 participate in the development of 
resistance. There are studies indicate that HER2 is one of the client proteins of HSP27. 
HER2 would be downregulated via inhibition of HSP27.  
Previously, a lead compound JCC76 which generated from COX-2 inhibitor 
 VII 
 
Nimesulide was found to target HSP27. Herein, 23 analogs of JCC76 were synthesized. 
Cell viability assay was used for screen the analogs that selectively inhibit HER2 
overexpressed cell proliferation. Western-blot and chaperone assay were used to 
investigate the anti-proliferate cellular mechanism. The selected compounds, 16 and 17, 
inhibited the protective function of small chaperone. In the HER2 downregulation 
experiment, the results indicate a dose-dependent downregulation of HER2 for both 
compounds. 
In the second study we try to improve the druggable characteristics of the 
compounds by reducing the compound size and molecular weight. Totally 60 compounds 
were synthesized and screen for cell growth inhibitory ability against variance cell line, 5 
compounds with potent proliferate inhibitory activity were identified. The SAR study 
indicates several compounds with 3-trifluoromethylbenzamide groups showed potent and 
selective inhibition of HER2 overexpressed breast cancer cells.  
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CHAPTER I 
INTRODUCTION 
 
 
1.1 Breast Cancer 
Cancer is a generic term for a large group of diseases that can affect any part of the 
body with one defining feature of rapid generation of abnormal cells that grow beyond 
their usual boundaries that can then invade adjoining parts of the body and spread to 
other organs. 
[1]
 Most cancers will form a lump or mass called a tumor, which can 
proliferate and spread throughout the body in a process known as metastasis. 
In the US, breast cancer is the second most common cancer in women after skin 
cancer, with a life time risk of about 12.4%. There are three major histopathology 
classifications of breast cancer: Ductal carcinoma in situ, Lobular carcinoma in situ, and 
Invasive breast cancer which consists of 80% of breast cancer. The American Cancer 
Society estimated there will be 252,710 cases of invasive breast cancer and 63,410 in situ 
breast carcinoma will be diagnosed among women, and 40,160 women are expected to 
die from breast cancer in 2017. 
[2] 
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The treatment of breast cancer depends on the stage of cancer. For early and locally 
advanced breast carcinoma the intention of treatment is to cure before metastasis, but for 
the later stage carcinoma there is no cure and the treatment is focused on increasing the 
overall survival rate. Various approaches employed for breast cancer management include 
surgery, radiation treatment, endocrine treatment and chemotherapy 
[3]
. Lumpectomy, a 
surgery to remove the tumor and a small, cancer-free margin of healthy tissue around the 
tumor will be used for stage I and II patients followed by radiation therapy. For local 
advanced carcinoma and patients with former radiation therapy to the breast or chest wall 
will go through mastectomy, which is the surgical removal of the entire breast, instead of 
lumpectomy. For stage IV breast cancer, only endocrine therapy and chemotherapy is 
available. To achieve best therapeutic results and improve the overall survival rate, an 
understanding of molecular biology behind breast cancer is necessary.  
Based on the expression level of classic immunohistochemistry (IHC) markers such 
as estrogen receptor (ER), progesterone receptor (PR) and human epidermal grow factor 
receptor 2 (HER-2) breast cancer can be divided into five intrinsic subtypes: Luminal A, 
Luminal B, HER2 over-expression, Basal and Normal-like (Table I). 
[4]
 In this study we 
are focusing on HER-2 over-expression subtype which tends to grow and spread more 
aggressively and has a poor prognosis and overall survival rate compared to the other 
subtypes. 
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Figure 1.1 Breast Cancer  
Astrid. Deodorant Alternatives for Avoiding Breast Cancer 
https://www.healyounaturally.com/deodorant-alternatives-for-avoiding-breast-cancer-ema
xhealth/ (accessed Mar 7, 2018). 
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Table 1.1   Summary of the breast tumor molecular subtypes 
[4]
 
 
 
  
Intrinsic subtype IHC status Grade Outcome 
Luminal A [ER+|PR+] HER2-KI67- 1/2 Good 
Luminal B [ER+|PR+] HER2-KI67+ 2/3 Intermediate 
 [ER+|PR+] HER2+KI67+  Poor 
HER2 over-expression [ER-PR-] HER2+ 2/3 Poor 
Basal [ER-PR-] HER2-, basal marker+ 3 Poor 
Normal-like [ER+|PR+] HER2-KI67- 1/2/3 Intermediate 
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1.2  Human Epidermal Growth Factor Receptor 2 (HER-2) 
 
1.2.1  HER2 in cancer 
Human Epidermal Growth Factor Receptor 2 (HER-2) is a 185 kDa glycoprotein 
encoded on gene 17q12 which is localized on the long arm of chromosome 17. It is 
normally expressed in the epithelia of various organs such as bladder, lung, breast, 
pancreas and prostate. HER-2 belongs to the transmembrane receptor tyrosine kinase 
(RTK) family, ErbB, which is a family of cell surface growth-factor receptors that play an 
important role in proliferation, migration, metabolism, differentiation, and survival of 
cells.
[5]
  
The ErbB family of proteins consists of four members: HER1 (EGFR, ErbB1), 
HER2 (Neu, ErbB2), HER3 (ErbB3), and HER4 (ErbB4) which are structurally related 
(Figure 1.2). Members of ErbB family have three major domains: ligand binding domain, 
transmembrane domain and kinase domain. The ligand binding domain can recognize and 
bind to various ligands with different specificity. Upon ligand binding, ErbBs will be 
active and be ready to form a homodimer or heterodimer. The numerous ErbB ligands can 
be divided into four categories based on their binding affinity toward different receptors. 
First category includes EGF, AR and TGFα which exclusively bind to EGFR. A second 
family consisting of BTC, HB-EGF and EPR show dual specificity toward HER1 and 
HER4. NRGs comprise the third and fourth family, and NGR-1 and NRG-2 can bind 
HER3 and HER4, NRG-3 and NRG-4 bind HER4 but not HER3.
[6]
 ErbB ligands have a 
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bivalence characteristic which shows high binding affinity toward the receptor and low 
affinity binding toward the dimerization partner. For instance, the ligand NRG–1’s 
preferential dimerization partner is HER2.
[7]
 There is no HER2 ligand that has been 
identified which is a characteristic related to HER2’s unique extracellular domain 
structure. The extracellular domain of the ErbB family consists of four subdomains (I-IV): 
subdomain I, II and III form the ligand binding pocket and the helic fold in subdomain I 
and III are critical for ligand binding. During ligand binding the receptor dimerization is 
through interaction between a beta hairpin in subdomain II. In contrast, in the inactivated 
ErbB the intramolecular interactions between subdomains II and IV will prevent 
dimerization. HER2 has a fixed conformation that resembles a ligand-activated state, and 
its subdomains I and III are very close where this interaction makes ligand binding 
impossible. 
[8]
 This unique extracellular domain of HER-2 allows it to exhibit ligand 
independent activity. 
   Upon ligand binding and dimer formation, the intrinsic tyrosine kinase will be 
activated and lead to the autophosphorylation of specific C-terminal tyrosine residues, 
except HER3 which has an impaired autophosphorylation function.
[9]
 Various proteins 
containing Src homology 2 and phosphotyrosine binding domain will bind to the 
C-terminal of receptor and initiate cell signaling via different pathways which include: 
RAS/RAF/MAPK, PI3K/AKT,  Phospholipase Cγ, Src kinase pathways, and STAT 
pathways.
[10]
 Apart from those tyrosine kinase pathways, there are studies that indicate 
that there is a novel pathway where the EGFR will be transported from the cell 
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membrane to the nucleus to regulate gene expression directly. 
[11]
 HER2 can only recruit 
Grb2 and shc on its intracellular domain to activate the RAS/RAF/MAPK pathway and 
the HER2 homodimer signaling is relatively weak. 
[6]
 Unlike the homodimer’s weak 
signal, the heterodimer of HER2 has prolonged and enhanced downstream signalling 
through two different layers of regulation. At the ligand binding and activation layer 
HER2 heterodimers exhibit a relaxed ligand specificity and a decreased ligand 
dissociation rate which prolongs the downstream signal. At the endocytosis and recycling 
layer ErbB dimerizes with HER2 which will decrease the endocytosis rate. The HER2 
heterodimer will readily dissociate in early endosome and will be recycled back to the 
membrane. 
[12] 
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Figure 1.2  The ErbB receptors and their ligands. 
[6] 
Binding specificities of the EGF‐related peptide growth factors. There are four 
categories of ligands that bind ErbB family receptors. EGF, AR and TGFα bind ErbB1; 
BTC, HB‐EGF and EPR bind ErbB1 and ErbB4; NRG‐1 and NRG‐2 bind ErbB3 and 
ErbB4; and NRG‐3 and NRG‐4 bind ErbB4. 
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Among all ErbBs heterodimers, HER2/HER3 dimer can generate the most potent 
downstream signal to stimulate proliferation through the PI3K/AKT pathway. Hence 
there is research which indicate that HER3 is an indispensable HER2 dimerization 
partner and is essential for HER2 overexpressed tumor cell proliferation. Therefore 
HER2/HER3 dimer can be regarded as an oncogenic unit of HER2 overexpressed cancer. 
[13] 
 
 
1.2.2 HER2 targeting drug trastuzumab and its resistance 
Currently, two groups of HER2 targeting drugs exist. The first group is HER2 
monoclonal antibody which includes trastuzumab approved by the FDA in 1998 and 
pertuzumab approved in 2012. The second group is intracellular tyrosine kinase inhibitors 
such as lapatinib approved in 2007. 
[14]
 The exact mechanism of trastuzumab targeting 
HER2 overexpressed cancer remains unclear today. There are several proposed 
mechanisms, including blocking HER2 dimerization and extracellular domain proteolysis, 
recruiting immune effector cell and activating ADCC (antibody-dependent cellular 
cytotoxicity), receptor down regulation through endocytosis and degradation, and 
inhibiting DNA repair. 
[15],[16]
 
Although trastuzumab is one of the most effective treatments against HER2 
overexpressed breast cancer, a great number of patients do not benefit from it due to the 
resistance. There are multiple reasons for the resistance and the most intensively studied 
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trastuzumab resistance mechanisms can be divided into four: (1) obstacles for 
trastuzumab binding to HER2; (2) upregulation of HER2 downstream signalling 
pathways; (3) enhancing signalling through alternative pathways; and (4) failure to 
trigger immune-mediated mechanisms to destroy tumor cells. 
[15]  
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Figure 1.3  EGFR signalling pathway and targeted therapies
 [14] 
Currently there are two type of HER2 targeting agents They are targeting extracellular 
domain or kinase domain of HER2, see text for more detail  
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Besides these well studied mechanisms HSP27 (Heat shock protein 27) was also 
found to be involved in trastuzumab resistance. HSP27 expression was shown to be 
upregulated in trastuzumab resistance cells. The sensitivity of trastuzumab resistant cells 
to trastuzumab increased after HSP27 suppression by specific siRNA transfection. 
Co-immunoprecipitation analysis indicates that HSP27 can bind to HER2 in the absence 
of trastuzumab. 
[17]
 Based on another study, the neuropeptide, neuromedin U (NmU), is 
also involved in HSP27 induced trastuzumab resistance.
 [18]
 The proposed resistance 
mechanism is that the overexpressed HSP27 and NmU cooperatively stabilize HER2  
to downregulate its degradation which results in reduced trastuzumab susceptibility 
(Figure 1.4).  
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Figure1.4 Proposed mechanism of HSP27 induce trastuzumab resistance 
[18]
. HSP27 
is forming complex with neuromedin U to stabilize HER2 
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1.3 HSP27 and its regulation on client proteins 
 
1.3.1 HSP27 overview 
Heat shock proteins (HSPs) are a family of protein produced by the cell when 
exposed to stress conditions. HSPs are highly conserved proteins among species which 
were first discovered at 1962. This family of proteins were name after heat shock because 
they were first described related to heat shock, but now are known to be expressed when 
cells are exposed to various environmental, metabolic, and pathophysiological stress 
conditions.
 [19,20]
 HSPs are divided into six major families based on their molecular 
weight: HSP100, HSP90, HSP70, HSP60, HSP40 and small HSP (30KDa-15KDa). 
[21]
 
The higher molecular weight HSPs are ATP-dependent chaperones whereas small 
molecular HSPs are ATP-independent chaperones. Heat shock protein 27 (HSP27/HSPB1) 
belongs to the small heat shock protein family which contains 10 members characterized 
by a highly conserved central domain and less conserved N- and C-terminal domains. 
Small chaperone exists in monomer, dimer, and oligomers, and the dynamic 
oligomerization and function of the small chaperones is regulated by phosphorylation of 
the protein 
[22]
 
 
1.3.2 The ability of HSP27 regulate level of certain client proteins 
Besides chaperone function and protect cell against various stress, HSP27 also play 
an important role in diverse cellular pathway due to its complicate and dynamic oligomer 
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structure and phosphorylation statue. Among these interactions there are several proteins 
that are stabilized by HSP27, the category of these proteins including: receptors, 
transcript factors and some enzymes.
 [23] 
These proteins are stabilized by HSP27 and 
directly interact with HSP27, they can consider as the client proteins of HSP27. 
There are three transcript factors identified as the client proteins of HSP27 including: 
signal transducer and activator of transcription 2 (STAT2), signal transducer and activator 
of transcription 3 (STAT3) and zinc finger protein SNAI1 (Snail).
 [24]
 STAT2 as one of the 
HSP27’s client proteins was report by Gibert et al. [21] In this research the downregulation 
of STAT2 in HSP27 depletion cell was revealed by western-blot analysis. The reduction 
of STAT2’s activity was confirmed by monitoring the expression of luciferase in HSP27 
depletion cell transfected with a STAT1/STAT2-responsive luciferase construct encoding 
the firefly luciferase reporter gene. In further investigation of HSP27 regulation 
mechanism STAT2 degradation obstructed via proteasomal pathway inhibited by MG132, 
in qPCR test STAT2 mRNA slightly induce when level of STAT2 decrease in HSP27 
depletion cell. All these results support that HSP27 stabilizes STAT2 through preventing 
STAT2 degradation by proteasome.
 [25]
 In a study done by Rocchi et al, the 
downregulation of STAT3 via HSP27 knocked down with allele-specific oligonucleotide 
(ASO) has been reported. Although the exact mechanism is not clear about how HSP27 
regulates STAT3, at least that HSP27 participates in STAT3 protein complex was 
confirmed.
 [26]
 Inhibiting HSP27 resulting in to the reduction of STAT3 was also be 
observed in first trimester human placenta.
 [27]
 The upregulation of Snail was found in 
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adenocarcinoma cell due to overexpression of transforming growth factor beta 1 (TGF-β1) 
or HSP27. The result of Western-blot and qPCR studies on HSP27 depleted but TGF-β1 
overexpressed cell suggest that HSP27 regulate Snail at protein level instead of mRNA 
level. To confirm whether HSP27 stabilized Snail by decreasing proteasome degradation, 
HSP27 knocked down cells were treated with MG132 and the induction of Snail was 
restored. This result indicates that HSP27 upregulates Snail by preventing it from 
degradation.
 [28]
  
Two enzymes including human double minute 2 homolog (HDM2) and Histone 
deacetylase 6 (HDAC-6) are also identified as HSP27 client proteins.
 [24] 
In a study done 
by Ocallaghan-Sunol et al, HSP27 was found to stabilize HDM2 which further activates 
Tumor protein p53 (p53) pathway. 
[29] 
In the study done by Gibert et al, HDAC-6 was 
found to be downregulated in HSP27 knocked down cells and qPCR study suggests that 
HDAC-6 reduction was post-translationally regulated. To better understand the 
mechanism of HDAC-6 regulation by HSP27, HSP27 depletion HeLa cells were treated 
with proteasome inhibitor MG132 or ALLN. Both proteasome inhibitors were found to 
block the reduction of HDAC-6, suggest that HSP27 regulates HDAC-6 through 
degradation pathway.
 [25] 
HER2 and androgen receptor (AR) have been identified as client proteins of HSP27 
and they are important cancer therapeutic targets.
 [23] 
In a study done by Zoubeidi et al the 
interaction between HSP27 and AR was investigated. Androgen binding AR induces the 
phosphorylation of HSP27, and HSP27 could facilitate the AR complex shift to the 
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nucleus and induces the transcription activity of AR. HSP27 knocked down could reduce 
AR stability, which has been confirmed. They propose a pathway of HSP27 and AR 
interaction: androgen and androgen receptor binding could induce the phosphorylation of 
HSP27 and exchange partner from HSP90 to phosphorylated HSP27. The HSP27/AR 
complex will relocate into nucleus and promote transcription. inhibition of HSP27 
phosphorylation or reducing HSP27 with siRNA could reduce AR translocation and 
increase AR degradation.
 [30] 
There is another study suggest that HSP27 also mediates AR 
through regulating AR mRNA level.
 [31]
 
The interaction of HSP27 and HER2 were first reported by Kang et al. They found 
in trastuzumab resistance breast cancer cell line that the expression of HSP27 has been 
upregulated. Treatment with trastuzumab could lead to HER2 degradation in both 
trastuzumab resistance and naïve HER2 positive cell line. However HER2 reduction in 
resistance cell line is much less after the treatment, suggesting that increase of HER2 
stability may involve in trastuzumab resistance. The co-immunoprecipitation study shows 
that HSP27 can bind to HER2. After HSP27 knock down, trastuzumab resistance cell 
showed greater response when treated with trastuzumab and cell viability assay suggest 
that knock down HSP27 results in sensitizing resistance cells to trastuzumab. All this 
results suggest that downregulation of HER2 by trastuzumab can be blocked by the 
formation of HER2/HSP27 complex.
 [17] 
In another research done by the same group, the 
relationship between HSP27 phosphorylation and HER2 stabilization was investigated. 
Although HSP27 phosphorylation inhibitor suppressed cell proliferation and induced 
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apoptotic cell death in both HER2 positive breast cancer cell and trastuzumab resistance 
cells, there is no evident to support that the interaction between HER2 and HSP27 could 
be directly targeted by HSP27 phosphorylation inhibitor.
 [33] 
Neuromedin U (NmU) has 
been report to stabilize HER2 as a partner protein directly binding HSP27
 [34] 
  
 
1.3.3 HSP27 inhibition could induce degradation of certain client proteins 
Upregulation of HSP27 results in the enhanced stability of several client proteins 
which are critical cancer therapeutic targets. Therefore inhibition of HSP27 serves as a 
promising strategy to develop new anti-cancer agents. Currently there are four class of 
inhibitor that can regulate the expression level and function of HSP27.
 [35]
 First class is 
antisense oligonucleotide (ASO) that is a chemically modified or unmodified 
single-stranded DNA which binding to mRNA to prevent translation. OGX-427 is an 
ASO HSP27 inhibitor which can sensitize no-small cell lung cancer and bladder cancer to 
chemotherapy. 
[36,37] 
Downregulation of HSP27 by OGX-427 leads to the increased 
degradation of eukaryotic translation initiation factor 4E (eIF4E) in prostate cancer cells.
 
[38] 
Currently the phase II trial of OGX-427 on pancreatic cancer and no-small cell lung 
cancer are completed.
 [39] 
Second class of inhibitor is siRNA which is a double-stranded 
RNA which binding to mRNA and preventing its translation. Currently there is no siRNA 
drug on clinical trial but its ability to downregulate client protein of HSP27 has been 
reported. 
[25-31] 
The third class of inhibitor is peptide aptamers which is a selected or 
engineered peptide that can bind to specific target. Two sequence-specific aptamers has 
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been generated and prove to be able to reducing HSP27 but whether they can modify 
client protein or not has not been investigated.
 [40]
 The fourth class is small molecular 
inhibitor such as RP101, KRIBB3 and quercetin, which has been reported to inhibit 
HSP27 in the in vitro assays. RP101 has been prove to bind to mRNA coding therefore 
inhibit the translation leading to the downregulation of HSP27. 
[41] 
KRIBB3 was reported 
binding to HSP27 and inhibit its phosphorylation which lead to obstruct of tumor cell 
migration.
 [42] 
Quercetin was first reported to reduce the expression of HSP90, HSP70 and 
HSP27.
 [43] 
But late study indicate quercetin also capable to inhibit the phosphorylation of 
HSP27
 [44] 
However there is no research investigate the interaction between these small 
molecular inhibitor and client proteins. Our group has identified Copalic acid and its 
analogs as small chaperone inhibitor. This natural product inhibits the chaperone activity 
of HSP27 and α-crystallin in the in vitro insulin aggregation assay. In addition, the 
compounds were also found to induce AR degradation. Targeting the small chaperone 
proteins with small molecule inhibitors has the potential to induce onco-protein 
degradation, and be used as novel anti-cancer agents in the future.
[45] 
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CHAPTER II 
STATEMENT OF RESEARCH AND SPECIFIC AIMS 
 
 
2.1 Statement of research 
Cancer is the second cause of death in the US and the leading cause of death 
worldwide. Among various cancers, breast cancer is the most common one in females 
with 268,670 new cases expected in the United States in 2018. There are five intrinsic 
sub-types of breast cancer which are classified by the expression level of classic IHC. In 
this five sub-type HER2 overexpressed breast cancer accounts for about 20% of all breast 
cancer cases which is the most aggressive sub-type among the other four. And patients 
with this type of breast cancer have the lowest survival rate and the poorest prognosis. 
HER2 is a member of EGFR family and is overexpressed in multiple cancer types 
including breast cancer, ovarian cancer and lung cancer. HER2 has been a target for 
cancer therapy for decades; there are several drugs that have been developed. 
Trastuzumab, a monoclonal antibody drug, is the most successful HER2 targeting 
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therapeutic agent. However, half of HER2 positive breast cancer patients eventually 
ceased to respond to Trastuzumab due to the resistance caused by multiple different 
mechanisms. One of the resistance mechanisms is through the upregulation of the 
expression of HSP27 which stabilizes HER2. Therefore, inhibiting HSP27 could potential 
down-regulate HER2 protein and overcome the Trastuzumab resistance for breast cancer 
treatment. 
HSP27 a small chaperone protein is a novel target for cancer therapy since it has 
anti-apoptotic effects. Currently existing HSP27 targeting agents function through 
reducing expression, inhibiting kinase phosphorylation of HSP27 or interrupting the 
interaction between HSP27 and apoptosis proteins. The present situation suggests the 
need for developing an HSP27 inhibitor which can specifically interrupt the 
HSP27-HER2 pathway. 
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2.2 Specific aim 
(1) Synthesise a series of new compound by modify moiety B (Figure 2.1) to 
sulfonyl amide which should improve compounds’ solubility in aqueous phase and 
evaluate their ability of suppress cancer cell proliferate and inhibit Hsp27 function 
 (2) Synthesise a series of new compound by substitute moiety A (Figure 2.1) twith 
smaller functional groups which should reduce the hydrophobicity and improve 
compounds’ solubility in aqueous phase. Evaluate their anti-proliferate activity by cell 
viability assay. 
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Figure 2.1 structure of HSP27 inhibitor JCC76 
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CHAPTER III 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 
ANTI-CANCER AGENTS THAT SELECTIVELY INHIBIT HER2 
OVER–EXPRESSED BREAST CANCER CELL GROWTH VIA 
DOWN-REGULATION 
OF HER2 PROTEIN 
 
 
3.1  INTRODUCTION 
About 25–30% of breast cancer patients have human epidermal growth factor 2 
(HER2) over-expressed tumors, and the tumor cells depend on the HER2 pathway to 
proliferate.
[1]
 There are multiple factors that contribute to the high level of HER2 protein in 
tumors,
 [2,3]
 which results in constitutive activation of the receptor and cell growth. It has 
been well-documented that patients with over-expressed HER2 are associated with 
increased disease recurrence, worse prognosis and lower survival.
[4]
 Targeting the 
extracellular domain of Her2 receptor could result in an efficient inhibition of breast 
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cancer cell proliferation.
[1,2,5,6]
 In addition, inhibition of intracellular signaling pathways of 
HER2 downstream could lead to the suppression of cancer cell growth as well.
[7]
 Currently, 
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there are two types of drugs that target HER2. The first group is HER2 monoclonal 
antibody drugs such as trastuzumab approved by FDA in 1998; the second type is 
intracellular tyrosine kinase inhibitors such as lapatinib approved by FDA in 2007.
 [8,9]
 
 
Even though treatment with these drugs showed great efficiency in clinic for HER2 
over-expressed breast cancer patients, resistance has been reported in patients who use 
trastuzumab as the treatment.
 [9]
 There are multiple reasons for the resistance, and further 
increased HER2 expression in the cancer cells after the treatment is one of them.
 [10]
 
Researchers used different strategies to reduce the HER2 level and found that the cancer 
cells regained the sensitivity to trastuzumab. 
[10]
 Therefore, new agents that can reduce the 
amount of HER2 in breast cancer cells indirectly needs to be used for the HER2 
overexpressed breast cancer treatment, which may also have the potential to overcome 
trastuzumab resistance.
 [11-13] 
Our goal is to identify new anti-cancer compounds that would selectively inhibit the 
growth of HER2 over-expressing breast cancer cells, and then investigate the mechanism 
of the pharmacological activity. Previously we identified a small molecule, JCC76 that 
showed selectivity to inhibit the growth of HER2 over-expressed breast cancer cells
 
. In 
this study, structural optimization was performed to improve the biological activity and the 
selectivity of the lead compound. The new analogs were evaluated with a panel of breast 
cancer cell lines including SKBR-3, MCF-7 and MDA-MB-231. The compounds that 
selectively inhibited the proliferation of SKBR-3 cells that is a HER2 overexpressed breast 
cancer cell line were selected. They were further examined with western blot assay to 
analyze their effect on the HER2 protein level. The results indicate that the new compound 
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significantly decreased the HER2 level in breast cancer cells. In addition, the compounds 
inhibited the small chaperone protein in the in vitro assay.  
 
  
3.2  RESULTS AND DISCUSSION 
 
3.2.1  Lead optimization and summarization of the structure-activity relationship 
(SAR) studies 
Previously, compound JCC76 was shown to selectively inhibit the growth of SKBR-3 
cells with an IC50 of 1~3 µM. JCC76 was also found to inhibit a small chaperone protein 
heat shock protein 27 kDa (HSP27). It has been reported that HER2 is a client protein of 
HSP27, which may explain the selectivity of JCC76 to HER2 over-expressed SKBR-3 
cells. To improve the potency, selectivity and ligand efficiency, we further optimized the 
structure of JCC76. Based on the structure activity relationship (SAR) summarized before, 
we either retained the 2, 5-dimethylbenzyl moiety or changed it to 2, 5-dimethoxybenzyl 
group (Figure 3.1). Then the sulfonamide moiety of JCC76 was changed to a flipped new 
sulfonamide structure and two carbons were removed to increase the ligand efficiency 
and solubility. Further, the amide moiety was constructed with various substituted 
benzamides to explore what the best function group could be for this moiety. The 
synthesis of the new analogs is described in schemes 1 and 2.   
These new compounds were synthesized using method adapted from previous studies. 
Since the sulfonamide moiety was flipped in the new analogs compared to JCC76, the 
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construction of the sulfonamide is different to the previous synthetic method. The rest of 
the benzyl and amide moieties were synthesized in a similar way. A total of 23 final 
compounds were synthesized. 
Consequently, they were examined for the potency and selectivity on the growth 
inhibition of three different breast cancer cells lines including SKBR-3, MCF-7, and 
MDA-MB-231. SKBR-3 cells are HER2 positive and estrogen receptor (ER) negative, 
while MCF-7 cells are HER2 negative and ER positive. MDA-MB-231 cells are HER2 
and ER negative. The results are summarized in Table 3.1.  
The IC50s of the cell growth inhibition of the compounds range from 0.13 µM to 
25.69 µM for SKBR-3 cells, 1.18 µM to 60.49 µM for MCF-7 cells, and 0.27µM to 38.99 
µM for MDA-MB-231cells. The selectivity is calculated by dividing the IC50s of the 
compounds from different cell lines (Table 1). Most compounds exhibited more potent 
growth inhibition of SKBR-3 cells compared to MCF-7 and MDA-MB-231 cells, as 
indicated by most of the selective index that are greater than 1. For SKBR-3 cells, SAR 
analysis suggests that the benzamide group of these compounds is critical for the 
biological activity. The electron-donating substitute such as the iodo group on the 
benzamide moiety overall enhanced the activity, as indicated by compounds 3 and 6. The 
electron-withdrawing groups such as trifluromethyl harmed the activity, as indicated by 
compounds 7 and 15. In terms of the 2, 5-dimethoxybenzyl and 2, 5-dimethylbenzyl 
moiety, it seems that the methoxy group is more beneficial to the activity than the methyl 
group. Compounds 19-23 are relatively less potent compared to the corresponding 
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dimethoxy analogs, even though they have electron-donating substitutes on their 
benzamide moiety. Compounds 16 with a napheylamide moiety and 17 with a 
4-methxyphenyl moiety showed the best potency and selectivity.   
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Figure 3.1. Lead optimization of JCC76 to improve the ligand efficiency and 
biological activity   
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Figure 3.2 (a) NH3,H2O,THF; (b) CH2Cl2, BBr3; (c) 2,5-dimethoxybenzyl 
chloride, K2CO3, DMF; (d) 2,5-dimethylbenzyl chloride, K2CO3, DMF 
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Figure 3.3. (e) FeCl3, Zn, DMF/H2O; (f) RCOCl, K2CO3, 1,4-dioxane  
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Table 3. 1. Comparison of the growth inhibitory effects of 
the new analogs on different breast cancer cell lines 
 
Entry IC50(µM) 
(SKBR-3) 
IC50(µM) 
(MDA-231) 
IC50(µM) 
(MCF-7) 
Selectivity 
MDA231/SKBR-3 
Selectivity 
MCF-7/SKBR-3 
1 4.03±2.47 7.95±4.34 4.1±0.22 2.0 1.0 
2 3.44±1.35 15.92±2.56 8.02±1.65 4.6 2.3 
3 1.09±0.97 4.58±1.7 5.25±1.53 4.2 4.8 
4 4.38±1.25 23.01±7.67 10.52±0.69 5.3 2.4 
5 25.07±6.64 36.74±25.02 14.7±3.25 1.5 0.6 
6 0.52±0.15 1.63±0.61 2.26±0.36 3.1 4.4 
7 25.69±11.03 60.49±23.83 38.99±14.65 2.4 1.5 
8 3.14±1.03 4.08±1.1 5±1.76 1.3 1.6 
9 3.14±0.46 6.91±3.42 9.01±4.48 2.2 2.9 
10 6.84±3.18 7.44±2.25 6.44±0.4 1.1 0.9 
11 6.25±1.28 13.5±7.83 21.71±0.69 2.2 3.5 
12 1.97±0.4 3.7±2.02 2.61±0.14 1.9 1.3 
13 0.71±0.34 1.54±0.94 2.87±0.31 2.2 4.0 
14 0.67±0.15 2.22±0.85 0.63±0.17 3.3 0.9 
15 15.81±6.98 15.77±7.39 24.58±3.14 1.0 1.6 
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16 0.13±0.06 1.18±0.86 0.27±0.09 9.1 2.1 
17 2.09±0.11 12.8±8.98 3.38±0.62 6.1 1.6 
18 4.17±0.78 10.79±1.36 4.91±0.4 2.6 1.2 
19 3.01±0.49 6.63±0.62 4.44±0.71 2.2 1.5 
20 15.74±5.35 48.88±15.8 11.9±1.17 3.1 0.8 
21 15.05±3.89 10.29±0.72 9.7±2.16 0.7 0.6 
22 2.94±0.75 6.5±0.77 3.72±0.6 2.2 1.3 
23 11.22±1.16 20.99±0.81 10.18±0.41 1.9 0.9 
    
 
 
3.2.2 Compounds 16 and 17 down-regulate HER2 protein level    
 
Based on the selectivity and potency, compounds 16 and 17 were selected for further 
investigation. JCC76 was demonstrated to be a small chaperone inhibitor which also 
selectively inhibited SKBR-3 cell growth. As a client protein of the small chaperones, we 
hypothesize that JCC76 may be able to increase the degradation of HER2 via the 
inhibition of small chaperone protein. Previously, we demonstrated that small chaperone 
inhibitors could induce the degradation of the client proteins of the chaperones. SKBR-3 
cells were treated with JCC76 and compounds 16 and 17 for 48 h, and the Her2 level was 
determined by western blot assay. As exhibited in Figure 3.4,  
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Figure 3.4  Effect of compounds 16 and 17 on Her2 protein.  
SKBR-3 cells were treated with DMSO, JCC76 (1μM), compounds 16 (0.1, 0.3, 1μM) 
and 17 (0.1, 0.3, 1μM) for 48 h. Level of Her2 was analyzed by Western blot of cell 
extracts with specific antibodies. The bands of Her2 were quantified using ImageJ (NIH) 
and normalized to β-actin. The results are representative of three independent 
experiments. *p<.05 with unpaired t test, compound 16 vs JCC76 
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Her2 level was decreased by these candidates, and compounds 16 and 17 showed 
improved activity compared to JCC76, particularly compound 16 at 1 and 0.3 µM. The 
results demonstrate that the lead optimization increased the potency and selectivity of 
JCC76. In addition, the targeting effect of the compound is significantly increased as 
well.       
SKBR-3 cells were treated with DMSO, JCC76 (1µM), compound 16 (0.1, 0.3, 1µM) 
and 17(0.1, 0.3, 1µM) for 48h. The level of HER2 was analyzed by Western blot of cell 
extracts with specific antibody as described in experimental section. The bands of HER2 
were quantified using ImageJ (NIH) and normalized to β-actin. The results are 
representative of three independent experiments. * p<0.05 with unpaired t test, compound 
16 vs JCC76. 
 
 
3.2.3 Compounds 16 and 17 slightly inhibit small chaperones    
To examine if the new compounds could interfere with the chaperone function of 
small chaperone proteins, an in vitro chaperone assay was performed. As indicated in 
Figure 3, compounds 16 and 17 inhibited the protective function of small chaperone, 
α-crystalline, against DTT induced insulin denaturation and aggregation. The results 
demonstrate that the new analogs retained the chaperone inhibition property of the lead 
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compound. It has been reported that HER2 protein is a client protein of small chaperone 
protein HSP27, and inhibition of the small chaperone could induce HER2 degradation. 
Our new analogs showed inhibitory activity here. However, it is still unclear if the 
chaperone inhibition was the only mechanism for the decreased HER2 in SKBR-3 breast 
cancer cells. Further investigation is needed to look for other possible mechanisms.     
The kinetics of the DTT-induced insulin aggregation was monitored in the absence of 
a chaperone protein, or in the presence of a chaperone protein without or with compounds. 
The mixture of insulin and DTT with or without other components in the assay buffer 
was incubated for 45min at 37 ℃ and the absorbance at 400 nm was measured. The 
compounds at this concentration did not interfere with DTT and insulin interaction. The 
results are representative of three independent experiments.   
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Figure 3.5  α-Crystalline lost the activity to prevent DTT induced insulin aggregation in 
the presence of compounds 16 (10μM) and compound 17 (10μM). 
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3.3  CONCLUSION 
 
 We lead optimized JCC76 to improve the selectivity and potency of the compound 
to inhibit HER2 over-expressed breast cancer cell growth. By flipping the sulfonamide 
moiety of JCC76, we generated new analogs with better ligand efficiency, potency, and 
selectivity against SKBR-3 cells. Two compounds, 16 and 17, decreased the HER2 
protein level in SKBR-3 cells, which is speculated to be one of the main mechanisms of 
the selectivity and potency of the compounds. In addition, the compounds inhibited the 
small chaperone, α-crystalline, suggesting that they are potential small chaperone 
inhibitors.  
 
3.4.  EXPERIMENTAL 
 
3.4.1. Chemistry   
  
3.4.1.1 Synthesis of the new analogs(AZ) 
Chemicals were commercially available and used as received without further 
purification. Moisture sensitive reactions were carried out under a dry argon atmosphere 
in flame-dried glassware. Thin-layer chromatography was performed on silica gel TLC 
plates with fluorescence indicator 254 nm (Fluka). Flash column chromatography was 
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performed using silica gel 60Å (BDH, 40-63 μM). Mass spectra were obtained on the 
ABI QStar Electrospray mass spectrometer at Cleveland State University MS facility 
Center. All the NMR spectra were recorded on a Bruker 400 MHz (
13
C NMR at 100 MHz) 
using DMSO-d6 as solvent. Chemical shifts () for 
1
H NMR spectra were reported in 
parts per million to residual solvent protons. Reversed-phase HPLC analysis of 
compounds was conducted on a Beckman HPLC system with an Auto Sampler. The 
chromatographic separation was performed on a C18 column (2.0 mm × 150 mm, 5 μm) 
from Phenomenex (Torrance, CA). The mobile phase of 80% acetonitrile and 20% water 
was employed for isocratic elution with a flow rate of 0.2 mL/min. The injection volume 
was 20 µL and the UV detector was set up at 260 nm.  
 
 
The reaction procedure is illustrated in Schemes 1 and 2. Most of the steps follow the 
general methods described in our previous studies. Only the de-methylation is new and 
the procedure is described here. 
To de-methylate the methoxy group, a solution of 2-methoxy- 4-nitrobenzene 
sulfonamide (2.32 g, 10.0 mmol) in CH2Cl2 (30 mL) was cooled to -20 °C, and boron 
tri-bromide (6.01 g, 12.0 mmol) was added. The mixture was allowed to warm to room 
temperature over a period of 4 h and was then cooled to -20 °C; methanol (30 mL) was 
added, and the solution was concentrated. The solid residue was washed with ethyl 
acetate to obtain 2-hydroxy-4-nitrobenzenesulfonamide.  
The synthesis of the 2, 5-dimenthoxy benzyl intermediate and 2, 5-dimethyl benzyl 
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intermediate, the reduction of the nitro group, and the following benzamide construction 
are same to our previous published methods. The yield of the last step and the final 
compound characterization are described below.   
 
3.4.1.2 Structural characterization of 23 compounds of the new analogs(AZ)  
 
 N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-3-methoxybenzamide (1) 
3-methoxybenzoyl chloride was used, white solid, yield 71.7%. 1H-NMR (400MHz, 
DMSO-d6) δ 10.645 (1H,s), 7.810 (1H,s), 7.744 (1H,d), 7.540 (2H,t), 7.500 (1H,s), 7.464 
(1H,d), 7.269 (1H,d), 7.197 (1H,d), 7.000 (1H,s), 6.929 (2H,s), 6.871 (1H,m), 5.249 
(2H,s), 3.855 (3H,s), 3.817 (3H,s), 3.710 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 
166.109， 159.701， 155.525， 153.728， 150.845，144.441， 136.296， 130.127， 
128.744， 126.838， 125.462， 120.401， 118.101，114.720， 114.035， 113.569， 
112.190， 111.596， 105.144, 65.555， 56.288， 55.866， 55.807; DUIS-MS calculated 
for C23H24N2O7S, [M-H]-: 471.14, found 471.0; Purity: 99.8%. 
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Figure 3.6 The Chemical construction of N-(3-((2,5-dimethoxybenzyl) 
oxy)-4-sulfamoylphenyl)-3-methoxybenzamide 
 
 N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-3-methylbenzamide(2) 
3-methylbenzoyl chloride was used, white solid, yield 36.7%. 1H-NMR (400MHz, 
DMSO-d6) δ 10.462 (1H,s), 7.798 (2H,d), 7.744 (2H,d), 7.552 (1H,s), 7.439 (2H,d) 7.272 
(1H,d), 7.000 (1H,d), 6.928 (2H,s), 6.871 (1H,m), 5.251 (2H,s), 3.818 (3H,s), 3.711 
(3H,s), 2.418 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 166.502, 155.530, 153.729, 
150.842, 144.556, 138.282, 134.925, 132.998, 128.849, 128.752, 128.639, 126.743, 
125.478, 125.402, 114.716, 114.019, 112.194, 111.489, 105.047, 65.557, 56.294, 55.811, 
21.424; DUIS-MS calculated for C23H24N2O6S, [M-H]-: 455.15, found 455.0; Purity: 
99.7%   
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Figure 3.7  The Chemical construction of N-(3-((2,5-dimethoxy 
benzyl)oxy)-4-sulfamoylphenyl)-3-methylbenzamide 
 
 N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-3-iodobenzamide (3) 
3-iodobenzoyl chloride was used, white solid, yield 46.3%. 1H-NMR (400MHz, 
DMSO-d6) δ 10.555 (1H,s), 8.309 (1H,s) 7.976 (2H,t), 7.751 (2H,d), 7.530 (1H,d), 7.366 
(1H,t), 7.263 (1H,d), 7.000 (1H,d), 6.944 (2H,s), 6.870 (1H,m), 5.251 (2H,s), 3.817 
(3H,s), 3.781 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 164.838, 155.521, 153.729, 
150.826, 144.222, 140.932, 136.909, 136.451, 131.113, 128.792, 127.769, 127.026, 
125.446, 114.679, 114.022, 112.188, 111.639, 105.181, 95.192, 65.564, 56.293, 55.811; 
DUIS-MS calculated for C22H21IN2O6S, [M-H]-: 567.03, found 566.9; Purity: 93.7% 
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Figure 3.8 The Chemical construction of N-(3-((2,5-dimethoxy 
benzyl)oxy)-4-sulfamoylphenyl)-3-iodobenzamide 
 
 3-bromo-N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)benzamide(4) 
3-bromobenzoyl chloride was used, white solid, yield 33.2%. 1H-NMR (400MHz, 
DMSO-d6) δ 10.581 (1H,s), 8.159 (1H,s), 7.969 (1H,d), 7.833 (1H,d), 7.758 (2H,d), 
7.540 (2H,d), 7.264 (1H,s), 7.002 (1H,d), 6.949 (2H,s), 6.871 (1H,m), 5.255 (2H,s), 
3.819 (3H,s), 3.710 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 164.828, 155.520, 
153.723, 150.813, 144.187, 137.056, 135.136, 131.213, 130.771, 128.809, 127.466, 
127.062, 125.437, 122.185, 114.657, 113.999, 112.171, 111.642, 105.177, 65.549, 56.283, 
55.801;DUIS-MS calculated for C22H21BrN2O6S, [M-H]-: 519.04, found 520.9; Purity: 
99.5% 
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Figure 3.9  The Chemical construction of 3-bromo-N-(3- 
((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)benzamide 
 
 3-cyano-N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)benzamide (5) 
3-cyanobenzoyl chloride was used, white solid, yield 52.4 %. 1H-NMR (400MHz, 
DMSO-d6) 10.663 (1H,s), 8.417 (1H,s), 8.259 (1H,d), 8.104 (1H,s), 7.779 (1H,s), 7.758 
(2H,s), 7.528 (1H,s), 7.253 (1H,s), 7.001 (1H,d), 6.980 (2H,s), 6.870 (1H,d), 5.259 (2H,s), 
3.816 (3H,s), 3.703 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 164.542, 155.533, 
153.709, 150.790, 144.044, 135.930, 135.797, 133.095, 131.862, 130.393, 128.877, 
127.184, 125.405, 118.728, 114.601, 113.959, 112.156, 112.047, 111.632, 105.127, 
65.525, 56.280, 55.790; DUIS-MS calculated for C23H21N3O6S, [M-H]-: 466.13, found 
466.0; Purity: 99.9% 
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Figure 3.10  The Chemical construction of 3-cyano-N-(3-((2,5- 
dimethoxybenzyl)oxy)-4-sulfamoylphenyl)benzamide 
 
 N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-4-iodobenzamide (6) 
4-iodobenzoyl chloride was used, white solid, yield %.  1H-NMR (400MHz, 
DMSO-d6) 10.539 (1H,s), 7.950 (1H,d), 7.747 (2H,s), 7.727 (1H,s), 7.701 (1H,d), 7.523 
(1H,d), 7.250 (1H,s), 6.997 (1H,d), 6.952 (2H,s), 6.876 (1H,d), 5.243 (2H,s), 3.811(3H,s), 
3.700 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 165.715, 155.517, 153.718, 150.848, 
144.280, 137.835, 137.476 , 134.251, 131.923, 130.135, 128.774, 126.937, 125.433, 
114.705, 114.026, 112.210, 111.612, 105.158, 100.257, 65.556, 56.296, 55.807; 
DUIS-MS calculated for C22H21IN2O6S, [M-H]-: 567.03, found 567.0; Purity: 94.2% 
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Figure 3.11 The Chemical construction of N-(3-((2,5-dimethoxy 
benzyl)oxy)-4-sulfamoylphenyl)-4-iodobenzamide 
 
 N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-2,4-bis(trifluoromethyl)be
nzamide(7) 
2,4-bis(trifluoromethyl)benzoyl chloride was used, white solid, yield 24.3%. 
1H-NMR (400MHz, DMSO-d6) 10.992 (1H,s), 8.246 (2H,d), 8.018 (1H,d), 7.763 (1H,d), 
7.630(1H,s), 7.356 (1H,s), 7.235 (1H,s), 6.986 (3H,s) 6.872(1H,d), 5.248 (2H,s), 3.793 
(3H,s), 3.698 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 165.128, 155.658, 153.679, 
150.928, 143.607, 139.659, 131.295, 130.973, 130.508, 129.058, 127.449, 125.250, 
124.900, 124.686, 124.005, 122.187, 121.960, 114.806, 114.153, 112.230, 111.115, 
104.628, 65.535, 56.266, 55.785; DUIS-MS calculated for C24H20F6N2O6S, [M-H]-: 
577.10, found 576.9; Purity: 99.5% 
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Figure 3.12 The Chemical construction of N-(3-((2,5-dimethoxy 
benzyl)oxy)-4-sulfamoylphenyl)-2,4-bis(trifluoromethyl)benzamide 
 
 N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-4-(trifluoromethoxy)benza
mide (8) 
4-trifluoromethoxybenzoyl chloride was used, white solid, yield 61.3%. 1H-NMR 
(400MHz, DMSO-d6) 10.593 (1H,s), 8.092 (2H,d), 7.772 (1H,s), 7.751 (1H,d), 7.555 
(2H,d), 7.518 (1H,d), 7.251 (1H,s), 7.000 (1H,d), 6.944 (2H,s), 6.874 (1H,m), 5.253 
(2H,s), 3.815 (3H,s), 3.704 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 165.213, 155.514, 
153.701, 151.161, 150.813, 144.258, 134.033, 130.673, 128.813, 126.981, 125.415, 
121.226, 114.647, 113.971, 112.161, 111.570, 105.0855, 65.510, 56.274, 55.786;  
DUIS-MS calculated for C23H21F3N2O7S, [M-H]-: 525.11, found 525.0; Purity: 99.9% 
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Figure 3.13 The Chemical construction of N-(3-((2,5-dimethoxy 
benzyl)oxy)-4-sulfamoylphenyl)-4-(trifluoromethoxy)benzamide 
 
 3-chloro-N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)benzamide (9) 
3-chlorobenzoyl chloride was used, white solid, yield 52.0 %. 1H-NMR (400MHz, 
DMSO-d6) 8.031 (1H,s), 7.936 (1H,d), 7.768 (2H,d), 7.734 (1H,d), 7.605 (1H,d), 7.549 
(1H,d), 7.271 (1H,s), 7.000 (1H,d), 6.877 (2H,m), 5.262 (2H,s), 3.821 (3H,s), 3.713 
(3H,s); 13C-NMR (100MHz, DMSO-d6) δ 164.924, 155.521, 153.716, 150.812, 144.202, 
136.863, 133.741, 132.236, 130.963, 128.815, 127.953, 127.086, 127.050, , 125.429, 
114.660, 113.979, 112.151, 111.639, 105.168, 65.549, 56.268, 55.791; DUIS-MS 
calculated for C22H21ClN2O6S, [M-H]-: 475.09, found 475.0; Purity: 99.6% 
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Figure 3.14 The Chemical construction of 3-chloro-N-(3-((2,5- 
dimethoxybenzyl)oxy)-4-sulfamoylphenyl)benzamide 
 
 N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-4-ethylbenzamide(10) 
4-ethylbenzoyl chloride was used, white solid, yield 56.0 %. 1H-NMR (400MHz, 
DMSO-d6) 10.417 (1H,s), 7.98 (2H,d), 7.810 (1H,s), 7.734 (1H,d), 7.543 (1H,d), 7.394 
(2H,d), 7.267 (1H,s), 7.000 (1H,d), 6.922 (2H,s), 6.870 (1H,d), 5.247 (2H,s), 3.817 
(3H,s), 3.709 (3H,s), 2.705(2H,m), 1.228 (3H,t); 13C-NMR (100MHz, DMSO-d6) δ 
166.255, 155.523, 153.725, 150.841, 148.675, 144.618, 132.335, 128.736, 128.355, 
128.303, 126.665, 125.479, 114.711, 114.020, 112.183, 111.458, 105.006, 65.538, 56.286, 
55.806, 28.555, 15.799; DUIS-MS calculated for C24H26N2O6S, [M-H]-: 469.16, found 
468.9;Purity: 99.9%. 
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Figure 3.15 The Chemical construction of N-(3-((2,5- 
dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-4-ethylbenzamide 
 
 4-cyano-N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)benzamide (11) 
4-cyanobenzoyl chloride was used, white solid, yield 31.3 %. 1H-NMR (400MHz, 
DMSO-d6) δ 10.720 (1H,s), 8.114 (2H,d), 8.044 (2H,d), 7.772 (1H,s), 7.760(1H,d), 7.246 
(1H,d), 6.995 (1H,d), 6.967(2H,s), 6.866 (1H,m), 5.255 (2H,s), 3.812 (3H,s), 3.701 
(3H,s); 13C-NMR (100MHz, DMSO-d6) δ 165.041, 155.544, 153.739, 150.843, 144.019, 
138.922, 132.991, 129.092, 128.842, 127.273, 125.426, 118.705, 114.661, 114.034, 
112.215, 111.715, 105.254, 65.564, 56.306, 55.809; DUIS-MS calculated for 
C23H21N3O6S, [M-H]-: 466.13, found 466.0; Purity: 91.3%. 
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Figure 3.16 The Chemical construction of 4-cyano-N-(3-((2,5- 
dimethoxybenzyl)oxy)-4-sulfamoylphenyl)benzamide 
 
 4-chloro-N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-3-nitrobenzamide 
(12) 
4-chloro-3-nitrobenzoyl chloride was used, white solid, yield 52.1 %. 1H-NMR 
(400MHz, DMSO-d6) δ 10.761 (1H,s), 8.642 (1H,s), 8.266 (1H,d), 7.995 (1H,s), 7.778 
(1H,s), 7.737 (1H,s), 7.516 (1H,d), 7.250 (1H,s), 7.000 (1H,d), 6.973 (2H,s), 6.871 
(1H,d), 5.262 (2H,s), 3.817 (3H,s), 3.704 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 
163.368, 155.543, 153.728, 150.805, 147.838, 143.819, 134.904, 133.415, 132.510, 
128.895, 127.392, 125.409, 114.615, 113.997, 112.191, 111.798, 105.299, 65.561, 60.226, 
56.298, 55.800; DUIS-MS calculated for C22H20ClN3O8S, [M-H]-: 520.08, found 520.0; 
Purity: 97.6% 
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Figure 3.17 The Chemical construction of 4-chloro-N-(3-((2,5- 
dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-3-nitrobenzamide 
 
 N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-3-ethoxybenzamide(13) 
3-ethoxybenzoyl chloride was used, white solid, yield 52.5 %. 1H-NMR (400MHz, 
DMSO-d6) δ 10.445 (1H,s), 7.816 (1H,s), 7.749 (1H,d), 7.545 (2H,d), 7.500 (1H,s), 
7.460 (1H,t), 7.276 (1H,s), 7.181 (1H,d), 7.000 (1H,d), 6.929 (2H,s), 6.875 (1H,d), 5.254 
(2H,s), 4.123 (2H,m), 3.819 (3H,s), 3.714 (3H,s), 1.375 (3H,t);13C-NMR (100MHz, 
DMSO-d6) δ 166.128, 158.944, 155.507, 153.705, 150.869, 144.432, 136.199, 130.163, 
128.718, 126.789, 125.424, 120.318, 118.437, 114.766, 114.070, 114.048, 112.209, 
111.604, 105.155, 65.563, 63.8435, 56.282, 55.799, 15.049; DUIS-MS calculated for 
C24H26N2O7S, [M-H]-: 485.16, found 485.1; Purity: 98.6% 
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Figure 3.18 The Chemical construction of N-(3-((2,5- 
dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-3-ethoxybenzamide 
 
 4-bromo-N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)benzamide(14) 
4-bromobenzoyl chloride was used, white solid, yield 53.3 %. 1H-NMR (400MHz, 
DMSO-d6) δ 10.563 (1H,s), 7.922 (2H,d), 7.788 (1H,s), 7.770 (2H,s), 7.743 (1H,d), 
7.525 (1H,d), 7.251 (1H,s), 7. 000(1H,d), 6.957 (2H,s), 6.867 (1H,d), 5.246 (2H,s), 
3.8115 (3H,s), 3.700 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 165.412, 155.505, 
153.704, 150.803, 144.274, 133.948, 131.978, 130.360, 128.798, 126.945, 126.263, 
125.425, 114.640, 113.968, 112.156, 111.584, 105.110, 65.516, 56.273, 55.790; 
DUIS-MS calculated for C22H21BrN2O6S, [M+H]+: 521.04, found 520.9; Purity: 98.7% 
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Figure 3.19 The Chemical construction of 4-bromo-N-(3-((2,5- 
dimethoxybenzyl)oxy)-4-sulfamoylphenyl)benzamide 
 
 N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-3,5-bis(trifluoromethyl) 
benzamide(15) 
3,5-bistrifluoromethylbenzoyl chloride was used, white solid, yield 30.0 %. 
1H-NMR (400MHz, DMSO-d6) δ 10.875 (1H,s), 8.612 (2H,s), 8.394 (1H,s), 7.802 
(1H,d), 7.7571 (1H,s), 7.264 (1H,s), 7.000 (1H,d), 6.986 (2H,s), 6.871 (1H,m), 5.275 
(2H,s), 3.818 (3H,s), 3.709 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 163.489, 155.557, 
153.723, 150.791, 143.758, 137.180, 131.158, 130.827, 129.130, 128.902, 127.482, 
125.376, 124.909, 122.195, 114.608, 113.990, 112.168, 111.971, 105.422, 65.587, 56.259, 
55.776; DUIS-MS calculated for C24H20F6N2O6S, [M-H]-: 577.10, found 577.0; Purity: 
97.6%. 
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Figure 3.20 The Chemical construction of N-(3-((2,5-dimethoxybenzyl)oxy)-4- 
sulfamoylphenyl)-3,5-bis(trifluoromethyl)benzamide 
 N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-1-naphthamide(16) 
1-naphthoyl chloride was used, white solid, yield 52.8 %. 1H-NMR (400MHz, 
DMSO-d6) δ 8.606 (1H,s), 8.110 (1H,d), 8.073 (1H,s), 8.040 (2H,s), 7.845 (1H,s), 7.768 
(1H,s), 7.663 (2H,m), 7.280 (1H,s), 7.007 (1H,d), 6.877 (1H,d), 5.2720 (2H,s), 3.825 
(3H,s), 3.714 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 166.466, 155.557, 153.721, 
150.835 144.635, 134.893, 132.490, 132.208, 129.499, 128.802, 128.734, 128.596, 
128.520, 128.180, 127.428, 126.778, 125.479, 124.869, 114.713, 113.988, 112.169, 
111.562, 105.108, 65.578, 56.282, 55.806; DUIS-MS calculated for C26H24N2O6S, 
[M-H]-: 491.15, found 491.1;Purity: 98.7% 
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Figure 3.21 The Chemical construction of N-(3-((2,5-dimethoxy 
benzyl)oxy)-4-sulfamoylphenyl)-1-naphthamide 
 
 N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)-4-methoxybenzamide(17) 
4-methoxybenzoyl chloride was used, white solid, yield 38.6 %. 1H-NMR (400MHz, 
DMSO-d6) 10.468 (1H,s), 7.807 (1H,s), 7.742 (1H,d), 7.520 (4H,m), 7.264(1H,s), 
7.200(1H,d), 7.003 (1H,d), 6.932 (2H,s), 6.870 (1H,m), 5.248 (2H,s), 3.856 (3H,s), 3.817 
(3H,s), 3.711 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 166.116, 159.700, 155.520, 
153.721, 150.849, 144.431, 136.287, 130.136, 128.739, 126.831, 125.453, 120.401, 
118.111, 114.726, 114.041, 113.555, 112.199, 111.603, 105.145, 65.553, 56.290, 55.867, 
55.807; DUIS-MS calculated for C23H24N2O7S, [M-H]-: 471.14, found 471.0; Purity: 
98.1% 
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Figure 3.22 The Chemical construction of N-(3-((2,5-dimethoxy 
benzyl)oxy)-4-sulfamoylphenyl)-4-methoxybenzamide 
 
 N-(3-((2,5-dimethoxybenzyl)oxy)-4-sulfamoylphenyl)cyclohexanecarboxamide(1
8) 
Cyclohexanecarbonyl chloride was used, white solid, yield 77.0 %. 1H-NMR 
(400MHz, DMSO-d6) δ 10.149 (1H,s), 7.660 (2H,d), 7.246 (2H,m), 6.992 (2H,d), 6.864 
(2H,m), 5.200 (2H,s), 3.807 (3H,s), 3.701 (3H,s), 2.341 (1H,t), 1.785 (4H,t), 1.658 (1H,d), 
1.3939 (32H,m), 1.228 (3H,m); 13C-NMR (100MHz, DMSO-d6) δ 175.370, 155.614, 
153.704, 150.867, 144.766, 128.774, 126.128, 125.463, 114.732, 114.069, 112.199, 
110.359, 103.865, 65.482, 56.298, 55.802, 45.4049, 29.484, 25.629;DUIS-MS calculated 
for C22H28N2O6S, [M-H]-: 447.18, found 447.0; Purity: 99.0% 
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Figure 3.23 The Chemical construction of N-(3-((2,5-dimethoxy 
benzyl)oxy)-4-sulfamoylphenyl)cyclohexanecarboxamide 
 
 N-(3-((2,5-dimethylbenzyl)oxy)-4-sulfamoylphenyl)-4-iodobenzamide (19) 
4-iodobenzoyl chloride was used, white solid, yield 58.3%. 1H-NMR (400MHz, 
DMSO-d6) 10.547 (1H,s), 7.939 (2H,d), 7.776 (1H,s), 7.731 (3H,d), 7.461 (1H,d), 7.362 
(1H,s), 7.076 (2H,m), 6.963 (2H,s), 5.241 (2H,s), 2.333 (3H,s), 2.251 (3H,s); 13C-NMR 
(100MHz, DMSO-d6) δ 165.846, 155.849, 144.190, 137.844, 135.154, 134.473, 134.289, 
133.421, 131.549, 130.515, 130.143, 129.074, 128.937, 126.930, 111.492, 105.264, 
100.226, 68.702, 21.151, 18.504; DUIS-MS calculated for C22H21IN2O4S, [M-H]-: 
535.04, found 534.9; Purity: 96.7% 
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Figure 3.24 The Chemical construction of N-(3-((2,5- 
dimethylbenzyl)oxy)-4-sulfamoylphenyl)-4-iodobenzamide 
 
 N-(3-((2,5-dimethylbenzyl)oxy)-4-sulfamoylphenyl)-3-iodobenzamide(20) 
3-iodobenzoyl chloride was used, white solid, yield 55.8%.1H-NMR (400MHz, 
DMSO-d6) 10.566 (1H,s), 8.288 (1H,s), 7.975 (2H,t), 7.779 (1H,s), 7.745 (1H,d), 7.477 
(1H,d), 7.380 (1H,s), 7.084 (2H,m), 6.942 (2H,s), 5.248 (2H,s), 2.343 (3H,s), 2.264 
(3H,s); 13C-NMR (100MHz, DMSO-d6) δ 164.960, 155.859, 144.124, 136.953, 136.440, 
134.484, 131.148, 130.515, 129.117, 128.944, 127.757, 127.045, 111.550, 105.342, 
95.157, 68.749, 21.151, 18.510; DUIS-MS calculated for C22H21IN2O4S, [M-H]-: 535.04, 
found 534.9; Purity: 99.8% 
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Figure 3.25 The Chemicalstruction of  N-(3-((2,5- 
dimethylbenzyl)oxy)-4-sulfamoylphenyl)-3-iodobenzamide 
 
 N-(3-((2,5-dimethylbenzyl)oxy)-4-sulfamoylphenyl)cyclohexanecarboxamide 
(21) 
Cyclohexanecarbonyl chloride was used, white solid, yield 53.7%. 1H-NMR 
(400MHz, DMSO-d6) 10.097 (1H,s), 7.659 (2H,d), 7.352 (1H,s), 7.227 (1H,d), 7.110 
(1H,d), 7.075 (2H,m), 6.872 (2H,s), 5.205 (2H,s), 2.327 (3H,s), 2.252 (3H,s), 1.778 
(4H,t), 1.654 (1H,d), 1.399 (2H,m), 1.239 (3H,m); 13C-NMR (100MHz, DMSO-d6) δ 
175.386, 155.934, 144.688, 135.088, 134.522, 133.429, 130.477, 129.149, 128.952, 
128.881, 126.086, 110.156, 103.935, 68.587, 45.421, 29.485, 25.815, 25.622, 21.143, 
18.512. UIS-MS calculated for C22H28N2O4S, [M-H]-: 415.19, found 415.6; Purity: 
95.3% 
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Figure 3.26  The Chemical construction of N-(3-((2,5- 
dimethylbenzyl)oxy)-4-sulfamoylphenyl)cyclohexanecarboxamide 
 
 N-(3-((2,5-dimethylbenzyl)oxy)-4-sulfamoylphenyl)-4-methoxybenzamide(22) 
4-methoxybenzoyl chloride was used, white solid, yield 64.2%.1H-NMR (400MHz, 
DMSO-d6) 10.347 (1H,s), 7.964 (2H,d), 7.818 (1H,s), 7.718 (1H,d), 7.382 (1H,s), 7.082 
(4H,m), 6.9072(2H,s), 5.241(2H,s), 3.390(3H,s), 2.343 (3H,s), 2.261 (3H,s); 13C-NMR 
(100MHz, DMSO-d6) δ 162.679, 155.872, 144.659, 135.153, 134.543, 133.437, 130.509, 
130.248, 129.149, 128.940, 128.822, 126.919, 126.546, 114.194, 111.3683, 105.1611, 
68.731, 55.962, 21.151, 18.512 ; DUIS-MS calculated for C23H24N2O5S, [M-H]-: 
439.15, found 439.0; Purity: 98.9% 
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Figure 3.27 The Chemical construction of N-(3-((2,5- 
dimethylbenzyl)oxy)-4-sulfamoylphenyl)-4-methoxybenzamide 
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 4-bromo-N-(3-((2,5-dimethylbenzyl)oxy)-4-sulfamoylphenyl)benzamide(23) 
4-bromobenzoyl chloride was used, white solid, yield 58.1%.1H-NMR (400MHz, 
DMSO-d6) δ 10.561 (1H,s), 7.921 (1H,s), 7.901 (1H,s), 7.788 (2H,s), 7.767(1H,s), 7.743 
(1H,d), 7.479 (1H,d), 7.378 (1H,s), 7.118 (1H,d), 7.047 (1H,d), 6.940 (2H,s), 5.248 
(2H,s), 2.343(3H,s), 2.261 (3H,s); 13C-NMR (100MHz, DMSO-d6) δ 165.491, 155.862, 
144.211, 135.134, 134.525, 134.021, 133.388, 131.979, 130.496, 130.373, 129.061, 
128.915, 127.004, 111.485, 105.266, 68.698, 21.176, 18.527; DUIS-MS calculated for 
C22H21BrN2O4S, [M+H]+: 489.05, found 488.9; Purity: 99.4% 
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Figure 3.28  The Chemical construction of 4-bromo-N-(3-((2,5- 
dimethylbenzyl)oxy)-4-sulfamoylphenyl)benzamide 
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3.4.2.  Biological studies 
 
3.4.2.1. Cell culture.  
Three breast cancer cell lines including SKBR-3, MCF-7, and MDA-MB-231 
were obtained from ATCC (Rockville, MD). The cells were maintained in RPMI1640 
medium supplemented with 10% fetal bovine serum (FBS), 2 mmol/L L-Glutamine, 1 
mmol/L sodium pyruvate, 100 U/mL
 
penicillin-streptomycin. FBS was heat inactivated 
for 30 min in a 56 ºC water bath before use. Cell cultures were grown at 37 ºC, in a 
humidified atmosphere of 5% CO2 in a VWR CO2 incubator (Bridgeport NJ).  
 
 
3.4.2.2. Cell viability analysis 
The effects of the new derivatives on the viability of three breast cancer cell lines 
were assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H- tetrazolium 
bromide assay in four replicates. Cells were grown in RPMI1640 medium in 96-well, 
flat-bottomed plates for 24 h, and were exposed to various concentrations of the 
compounds dissolved in DMSO (DMSO final concentration 0.1%) in media for 48 h. 
Controls received DMSO vehicle at a concentration equal to that in drug-treated cells. The 
medium was removed, replaced by 200 µL of 0.5 mg/ml of 3-(4,5-dimethylthiazol-2-yl) 
-2,5-diphenyl-2H- tetrazolium bromide in fresh media, and cells were incubated in the CO2 
incubator at 37°C for 2 h. Supernatants were removed from the wells, and the reduced 
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3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyl- 2H-tetrazolium bromide dye was solubilized 
in 200 µL/well DMSO. Absorbance at 570 nm was determined on a plate reader. Statistical 
and graphical information was determined using GraphPad Prism software (GraphPad 
Software Incorporated) and Microsoft Excel (Microsoft Corporation). IC50 values were 
determined using nonlinear regression analysis.  
 
 
3.4.2.3. Western blot 
SKBR-3 cells were treated with JCC76 (1µM), compound 16 (0.1, 0.3, 1µM) and 
compound 17 (0.1, 0.3, 1µM) for 48 h. The cells were lysed, briefly sonicated, and 
centrifuged at 12000g 
loading
 
buffer for 5 minutes, electrophoresed on a 10% SDS-polyacrylamide
 
gel, and 
transferred onto polyvinylidene difluoride (PVDF) membrane. The membrane was 
blocked for 1 hour with 5% nonfat milk in PBST and then incubated with specific 
primary antibody (Cell Signaling). After
 
washing, the membrane was incubated
 
with 
horseradish-conjugated secondary antibody (Cell Signaling). The bands were visualized 
by chemiluminescence with ECL reagent (Thermo Scientific). 
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3.4.2.4. Small chaperone activity assay.  
Alpha-crystalline chaperone activity assay: 24 µlmg/ml insulin stock solution was 
added to the single well of 384 well plate, 3µl 5mg/ml alpha-crystalline, 71 µl PBS buffer 
with appropriate concentration of compound dissolved inside were added as well.  The 
mixture was thoroughly mixed and incubated at 37 ºC for 5 min, whereupon 2 µL of 1M 
DTT in water was added to initiate the insulin aggregation. The absorbance (A) at 400 
nm was monitored over 45min using a plate reader. A mixture of insulin in the absence or 
presence of alpha-crystalline with 0.1% DMSO was used as control.  
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CHAPTER IV 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF SMALL 
MOLECULES WITH IMPROVED DRUG CHARACTERISTICS TO 
INHIBIT THE GROWTH OF HER2 OVER-EXPRESSED BREAST 
CANCER CELL 
 
 
4.1 INTRODUCTION 
About 25-30% of breast cancer patient have human epidermal growth factor receptor 
2 (HER2) overexpressed tumors, and the tumor cell rely on HER2 pathway to survive and 
proliferate.
 [1]
 HER2 is a ligand independent RTK, overexpress HER2 result in constitutive 
activation of the receptor which stimulate cell growth and metastasis.
 [2]
 It has been well 
documented that overexpressed HER2 in breast cancer relate to poor prognosis and lower 
survival rate. 
[3]
 Targeting HER2 has become a promising strategy to develop breast cancer 
therapeutic agent. Currently there are three type of drug that targeting HER2. The first 
group is HER2 monoclonal antibody drugs such as trastuzumab approved by FDA in 1998; 
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the second group is antibody-drug conjugate base on first group drug such as 
trastuzumab emtansine approved by FDA in 2013; the third group is intracellular tyrosine 
kinase inhibitors such as lapatinib approved by FDA in 2007.
[4-6] 
Even though trastuzumab has become a successful drug for treating HER2 
overexpressed breast cancer, still there are a great number of patient didn’t gain benefit 
from this therapy due to de novo or acquire resistance.
 [5]
 There is several pathways involve 
in trastuzumab resistance development.
 [7]
 Up-regulated HER2 is one of the resistance 
mechanisms. It has been reported that long term treatment of breast cancer cells with 
trastuzumab leads to HER2 expression increase. The further increased HER2 compensate 
the targeting effect of trastuzumab, which is the main reason of the resistance. Based on the 
resistance mechanism, targeting HER2 to decrease its expression and increase its 
degradation could solve the resistance. 
Previously, we found that small chaperone inhibitors have the potential to increase 
HER2 degradation. In this study our goal is to develop drug candidates with better 
druggable characteristics to selectively target HER2 overexpressed breast cancer, and 
further examine if the identified compounds induce HER2 degradation via small chaperone 
inhibition. Ligand efficiency is an important factor that may affect the efficacy of the 
compound. Drug candidates with better ligand efficacy have better permeability in the in 
vivo system. Therefore, the in vivo activity of these compounds should be better than 
compounds with lower ligand efficacy. In this study we tried to reduce the size and 
hydrophobicity of lead compound JCC76 from our previous study to maintain selectivity 
and improve solubility and cell uptake. 
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Figure 4.1 structure of lead compound JCC76 
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4.2 RESULTS AND DISCUSSION 
 
4.2.1 Lead optimization and summarization of structure-activity relationship (SAR) 
studies 
In last chapter, we tried to improve compound’s solubility by flipping the 
sulfonamide moiety of JCC76. Via flipping the sulfonamide we expose two hydrogen 
bond proton donors which should improve compound’s aqueous phase solubility. 
Through biology study we have confirmed those compound preserve ability to inhibit 
small chaperone, and induce HER2 degradation. Following the same principle, we 
hypothesize that further increase the ligand efficacy may even lead to better drug 
candidates.  
In this study we attempt to improve compound’s solubility and cell uptake by reduce 
molecule size and increase polarity. In previously study we have confirmed that by 
replace the 2,5-dimethylbenzyl in B moiety with 2,5-dimethoxylbenzyl the potency of 
inhibitor induce. We wonder if remove this highly hydrophobic group on the compound 
will it preserve the ability to inhibit HSP27 and selectively constrain the growth of HER2 
overexpressed breast cancer cell. To reduce molecule weight the 2,5-dimethylbenzyl 
group in B moiety was substitute with smaller function groups including methyl, 
methoxy, fluoro and chloro. 
In previously study the general order of potency of sulfonamides for inhibition of 
SKBR-3 cell growth has been identity which is methanesulfonamides > 
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ethanesulfonamides ≥ propylsulfonamides > benzylsulfoylamides > phenylsulfonamides. 
The larger of the sulphonamide the less cell growth inhibition which suit our compound 
design. In A moiety three sulfonamide substitutions: methanesulfonamide, 
ethanesulfonamide and trifluoromethanesulfonamide were choose to synthesized the new 
derivatives, methanesulfonamide and ethanesulfonamide were choose because of their 
potency and low molecular weight. We select trifluoromethanesulfonamide not just 
because of its small molecule size but we also interesting in whether this highly polar 
substitution could be tolerated or not. 
In previously study we discover that at C moiety bulky electron donating group is 
favour over electron withdraw group. However bulky electron donating group will induce 
the hydrophobicity of the compound and limit the solubility and cell uptake. From the 
result of cell viability assay of previously study 5 highly polar substitution groups exhibit 
potent SKBR-3 cell proliferate inhibition were choose. The substation group at C moiety 
are: 4-chloro benzylamide, 4-cyano benzylamide, 3-trifluroumethyl benzylamide, 3-nitro, 
4-chloro benzylamide and 3,5-bis trifluroumethyl benzylamide. The potency of 
synthesized compounds inhibition against HER2 overexpressed breast cancer cell growth 
inhibition were test by cell viability assay.  
For SKBR-3 cell only two types of analogs exhibited potent anti-proliferate activity. 
First type is compound with 3-nitro, 4-chloro benzoyl amide substitution group. However, 
this category of analogs lack selectivity which may be related to the general cytotoxicity 
of the nitro group. The second type of analogs contain 3-trifluoromethybenzoyl amide 
 82 
 
substitution group. The SAR analysis indicates that the strong electronegative group on B 
moiety favor SKBR-3 proliferation inhibition whereas the electron withdrawing group 
trifluoromethyl on sulfonamide negatively affects the compounds’ activity. 
In C38 cells, several compounds with 3,5-bistrifluoromethybenzoyl amide 
substitution group showed some potent anti-proliferate activity, especially compound 5 
with IC50 value at 0.9μM. This result suggests that the new analogs may interfere with 
unknown cell growth pathway other than the HER2-HSP27 pathway. 
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Figure 4.2  Development of HSP27 inhibitor 
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Table 4.1 Comparison of the growth inhibitory effects of 
the new analogs on different cell lines(the specific structures of the compounds are 
included in the experimental section) 
 
Entry IC50(µM) 
(SKBR-3) 
IC50(µM) 
(MDA-231) 
IC50(µM) 
(MCF-7) 
IC50(µM) 
(HEK293) 
IC50(µM) 
(C38) 
1 240.13±83.26 >250 >250 50.26±13.57 69.05±20.12 
2 >250 >250 142.85±45.63 43.53±8.54 171.12±68.07 
3 126.28±23.43 79.76±5.69 84.41±41.5 17.49±14.24 13.87±6.70 
4 18.32±7.43 15.28±4.47 15.78±4.46 39.86±7.11 20.41±5.73 
5 >250 84.41±7.80 122.28±21.25 >250 0.98±0.74 
6 159.95±14.86 91.73±36.28 >250 125.43±27.20 68.71±11.88 
7 >250 145.45±21.86 >250 >250 108.76±16.77 
8 105.71±21.65 54.95±13.86 90.83±22.86 209.63±56.26 113.91±28.44 
9 19.33±20.10 28.34±8.83 28.1±14.28 35.47±8.99 71.23±29.97 
10 126.12±35.72 112.9±31.99 125.15±22.49 >250 30.60±11.92 
11 39.21±11.34 57.25±10.66 52.84±30.60 200.5±62.06 35.36±14.04 
12 233.65±49.92 >250 >250 >250 135.4±24.58 
13 65.36±9.84 153.58±32.67 247.45±120.26 130.60±32.20 8.72±6.18 
14 >250 211.6±66.65 130.99±34.85 >250 89.78±24.65 
15 37.73±6.27 0.63±0.73 74.93±25.09 38.73±14.75 19.66±7.35 
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16 >250 215.48±49.05 210.93±94.35 >250 70±16.32 
17 >250 142.98±26.55 191.2±51.02 >250 >250 
18 29.89±25.57 96.48±7.53 >250 >250 84.77±27.70 
19 19.98±14.37 >250 17.25±3.79 164.4±37.51 >250 
20 218.73±61.27 90.61±21.10 118.2±52.1 41.97±17.57 >250 
21 240.79±162.24 91.43±47.52 172.28±37.97 >250 60.09±31.85 
22 >250 149.47±42.46 >250 >250 66.44±29.82 
23 7.05±4.77 194.58±90.04 183.5±32.90 >250 84.83±41.66 
24 17.04±2.39 20.05±3.15 17.25±3.79 63.65±18.13 5.66±2.95 
25 >250 >250 >250 >250 32.71±18.78 
26 61.57±20.75 116.63±80.60 174.5±37.98 >250 108.48±46.66 
27 55.43±20.54 109.60±75.54 >250 >250 201.47±80.81 
28 107.47±40.26 100.14±36.64 >250 >250 75.23±14.75 
29 41.80±17.44 37.57±23.79 102.41±15.53 180.65±45.41 54.08±20.70 
30 >250 67.72±47.29 98.51±53.21 >250 >250 
31 147.7±47.33 217.68±15.38 >250 167.45±30.03 79.94±49.27 
 
32 
>250 156.99±41.6 >250 >250 >250 
33 178.59±104.35 >250 >250 >250 >250 
34 60.98±9.15 181.225±48.86 127.23±13.38 203.57±29.44 43.60±22.23 
 86 
 
35 101.37±15.48 90.32±13.23 156.25±26.92 132.33±49.16 62.40±37.52 
36 51.89±7.99 25.24±14.54 99.07±13.13 45.64±11.6 22.18±6.19 
37 >250 126.5±16.76 >250 >250 226.08±114.47 
38 10.56±5.59 36.84±7.34 148.01±44.73 106.79±33.36 49.09±14.51 
39 14.78±3.45 8.48±3.87 10.39±5.75 35.33±6.45 8.65±4.21 
40 12.23±4.58 75.25±34.49 73.08±35.02 43.33±18.33 11.84±9.00 
41 77.14±11.92 75.70±33.31 83.74±41.06 190.9±63.12 47.15±6.39 
42 107.72±16.70 125.06±43.83 >250 >250 97.77±40.81 
43 49.98±7.08 129.3±17.82 137.2±21.13 209.85±39.02 55.82±7.79 
44 97.65±15.87 106.74±28.5 116.32±33.98 228.48±44.82 31.68±7.26 
45 79.07±15.83 113.97±38.49 79.35±57.63 >250 136.06±51.81 
46 121.66±38.63 110.63±16.50 74.25±30.12 216.2±9.88 22.25±6.64 
47 >250 97.47±9.76 >250 >250 >250 
48 21.88±12.09 88.52±51.93 >250 >250 32.29±15.69 
49 57.78±24.03 105.06±5.12 191.69±95.93 23.08±3.13 101.79±45.41 
50 67.61±22.46 141.69±89.26 >250 >250 124.94±70.28 
51 108.25±57.74 65.13±10.71 >250 53.37±4.83 151.92±73.77 
52 58.37±4.4 50.02±16.01 >250 26.36±6.79 107.38±49.13 
53 12.35±1.53 44.58±8.96 165.34±90.71 94.84±29.38 119.17±43.96 
54 9.42±3.5 25.84±8.64 24.59±14.81 6.69±0.83 34.66±14.98 
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55 92.43±9.22 163.28±42.03 104.21±18.2 >250 58.26±31.56 
56 85.86±18.92 147.97±103.29 198.82±90.25 78.98±41.12 3.27±1.78 
57 233.55±163.8 >250 0.11±0.07 171.6±40.12 >250 
58 24.79±2.46 196.165±186.2
6 
>250 151.7±31.83 34.44±20.47 
59 28.47±6.21 9.97±4.48 8.60±5.32 22.66±9.82 26.99±15.74 
60 66.41±13.63 >250 3.59±1.24 81.61±27.32 71.54±10.98 
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4.2.2  Study on the structural characterization of fluorinated compounds. 
 
The NMR spectra of fluorinated compounds are very complex. The reason is that the 
atomic number(I) of fluorine atoms is also 1/2. In 
1
HNMR, it can couple and splite of the 
H atoms separated by 1-4 bonds. The corresponding coupling constants are 
2
JHF=40-60Hz，
3
JHF=2-15Hz and 
4
JHF=0-5Hz
[11,12,13]
. When there is a fluorine atom on the benzene ring, 
there are coupling and splitting between the fluorine atom and the ortho-position H atoms. 
and even the meta-position H atoms. In 
13
C NMR there are coupling and splitting 
between the fluorine atom and the C atoms separated by 1-4 bonds. The corresponding 
coupling constants are 
1
JCF=150-350, 
2
JCF=20-60Hz，
3
JCF=4-20Hz，
4
JCF=0-5Hz
[11,12,13]
. If 
there is a fluorine atom on the benzene ring, it's going to couple and split the five carbon 
atoms but para-position carbon atoms. The three fluorine atoms in CF3 can divide the 
carbon atoms that are directly connected to the fluorine atoms or two or three bonds apart 
with the fluorine atoms into four peaks. . In this experiment the coupling and splitting of 
H-C-C-F(
2
JHF)，C-F(
1
JCF)，C-C-F(
2
JCF)，C-C-C-F(
3
JCF) were detected. According to the 
chemical shift and the coupling and splitting, compound (50) is used for the identification 
of 
1
HNMR and 
13
C NMR,as shown in figure 4X and figure 4X 
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Figure 4.3 The hydrogen spectrum signal belongs of the compound(50) 
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Figure 4.4 The carbon spectrum signal belongs of the compound(50) 
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4.3 CONCLUSION 
Some compounds from the new analogs selectively inhibited SKBR-3 cell 
proliferation with IC50 values at 10μM. However some compounds show unexpected 
potent inhibition against C38 cell proliferation, the most potent compound with IC50 
value at 0.8μM, which suggest that these compounds may have toxicity to the immune 
system, since C38 is a macrophage cell line and used here as a model of the immune 
system. 
 
 
4.4 EXPERIMENTAL 
 
4.4.1 Chemistry 
Chemicals were commercially available and used as received without further 
purification. Moisture sensitive reactions were carried out under a dry argon atmosphere 
in flame-dried glassware. Thin-layer chromatography was performed on silica gel TLC 
plates with fluorescence indicator 254 nm (Fluka). Flash column chromatography was 
performed using silica gel 60Å (BDH, 40-
ABI QStar Electrospray mass spectrometer at Cleveland State University MS facility 
Center. All the NMR spectra were recorded on a Bruker 400 MHz (13C NMR at 100 
MHz) using DMSO-d6 as solvent. Chemical shifts () for 1H NMR spectra were reported 
in parts per million to residual solvent protons. Reversed-phase HPLC analysis of 
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compounds was conducted on a Beckman HPLC system with an Auto Sampler. The 
chromatographic separation was performed on a C18 column (2.0 mm × 150 mm, 5 μm) 
from Phenomenex (Torrance, CA). The mobile phase of 80% acetonitrile and 20% water 
was employed for isocratic elution with a flow rate of 0.2 mL/min. The injection volume 
was 20 µL and the UV detector was set up at 260 nm. 
 
 
4.4.1.1 Synthesis of the new analogs(HB) 
 
The reaction procedure is illustrated in the scheme 1 and 2. The general synthesis 
method describe below, as Figure 4.5 and  Figure 4.6. 
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Figure 4.5 (a) NaH, DMF, Ethanesulfonyl chloride/ Methanesulfonyl chloride ; NaOH, 
Methanol, H2O; (b) DCM, K2CO3, Trifluoromethanesulfonic anhydride; (c) Acetone, Zn, 
FeCl3; (d) Acetone, Brine, saturated Na2CO3 solution, corresponding Benzoyl chloride 
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Figure 4.6 (a) TEA, DCM, Ethanesulfonyl chloride/ Methanesulfonyl chloride ; NaOH, 
Methanol, H2O; (b) DCM, K2CO3, Trifluoromethanesulfonic anhydride; (c) Acetone, Zn, 
FeCl3; (d) Acetone, Brine, saturated Na2CO3 solution, corresponding Benzoyl chloride. 
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 General method for the preparation of 2a-2d  
Sulfonamides 2a-2d were prepared from arylsubstituted 2-amino-5-nitrophenols 
1a-1b. Dissolve arylsubstituted 2-amino-5-nitrophenol (15.0mmol) in 40ml anhydride 
DMF add NaH (95% powder, 1.325 g, 52.5 mmol, 3.5equiv) into the solution stir at room 
temperature for 30min. After stir at room temperature for 30min corresponding sulfonyl 
chloride (45mmol, 3equiv) was added to the mixture the reaction continued overnight at 
room temperature. Quench the reaction with water and the mixture was neutralized with 
6N HCl until pH=1-2, yellow intermediate precipitated. Intermediate was collect by 
filtration and wash with water, which was used to the next reaction without further 
purification 
The intermediate was dissolve in 100ml methanol and 50ml 4N NaOH aq solution 
was added into the solution, stir at room temperature for 2h. After reaction completed 
neutralized the solution with 6N HCl until pH=1-2. The precipitate was collect by 
filtration and was with water and cold ether to provide desire product. 
 
 General method for the preparation of 2g-2j  
Sulfonamides 2g-2j were prepared from arylsubstituted 2-amino-5-nitrophenols 
1c-1d. Dissolve arylsubstituted 2-amino-5-nitrophenol (15.0mmol) in 150ml anhydride 
DCM, TEA was added into solution (105.0mmol, 7equiv). After TEA added 
corresponding sulfonyl chloride (45mmol, 3equiv) added into solution, reacted at room 
temperature overnight. After reaction completed DCM evaporated under vacuum added 
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200ml water added into the flask neutralized with 6N HCl until pH=1-2. Collect the solid 
intermediate by filtration. Wash the intermediate with water, which was used to the next 
reaction without further purification. 
 The intermediate was dissolve in 100ml methanol and 50ml 4N NaOH aq solution 
was added into the solution, stir at room temperature for 2h. After reaction completed 
neutralized the solution with 6N HCl until pH=1-2. The precipitate was collect by 
filtration and was with water and cold ether to provide desire product 
 
 General method for the preparation of 2e-2f and 2k-2l 
Trifluoroumethylsulfonamides 2e-2f and 2k-2l were prepared from arylsubstituted 
2-amino-5-nitrophenols 1a-1d. Dissolve arylsubstituted 2-amino-5-nitrophenol 
(15.0mmol) in 150ml anhydride DCM and K2CO3 (75mmol) was added to solution, then 
cool to 0℃. Trifluoromethanesulfonic anhydride (45mmol) was added into the solution 
dropwise. The resulting mixture was continuously stirred for 3 h at 0-5 °C. Water (30 mL) 
was added to quench the reaction. DCM was evaporated under vacuum, and then 6N HCl 
(10mL) was added to acidify the residue. The product was collected by filtration and 
washed with water and cool ether, then used for the next reaction without further 
purification. 
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 General method for the preparation of product 1-60 
Dissolve intermediates 2a-2l 1mmol in acetone 10ml and water 1ml. After 
intermediates dissolve into solvent Zn (10mmol, 10equiv) and FeCl3 (4mmol, 4equiv) 
were added into solution, the result mixture was stirred at room temperature for 1h. After 
the reaction completed the mixture was filtrate through celite to remove inorganic 
precipitate. The eluent was evaporated under vacuum. 
Redissolve the intermediate into 10ml acetone, the corresponding benzoyl chloride 
(1.1mmol, 1.1equiv) was added then 10ml brine and 10ml saturated K2CO3 solution. The 
result mixture was stirred at room temperature for 1h. After the reaction completed 
neutralized with 6N HCl until PH=1-2, acetone was evaporated under vacuum. The 
product was collect by filtration and purify by recrystallization in ethanol/ water (3:1). 
 
 
4.4.1.2 Structural characterization of 60 compounds of the new analogs (HB) 
 
 4-chloro-N-(4-(methylsulfonamido)-3-methylphenyl)benzamide（1） 
Yield 56.7%. 
1
H-NMR (400MHz, DMSO-d6) δ: 10.427(s,1H), 8.362(s,1H), 8.013 
(d,2H,J=8.0), 7.753(s,1H), 7.738(d,1H,J=8.0), 7.634(d,2H,J=8.0), 7.325 (d,1H,J=8.0), 
3.248(s,3H), 2.344(s,3H). 
13
C-NMR (100MHz, DMSO-d6) δ: 164.950, 138.947, 137.065, 
133.812, 133.458, 130.119(2C), 128.992(2C), 128.945,  125.696,  123.006,  119.310,  
43.628, 18.173. DUIS-MS calculated for C15H15ClN2O3S, [M-H]-: 337.04 , found336.9; 
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Purity: 95.3%. 
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Figure 4.7 The Chemical construction of 4-chloro-N-(4-(methyl 
sulfonamido)-3-methylphenyl)benzamide 
 
 4-cyano-N-(4-(methylsulfonamido)-3-methylphenyl)benzamide (2) 
Yield 60.5%.
1
H-NMR (400MHz, DMSO-d6) δ: 10.607 (s,1H), 8.362 (s,1H), 8.136 
(d,2H,J=8.4), 8.049(d,2H,J=8.4), 7.758(s,1H), 7.744 (d,1H, J=8.0),7.339 (d,1H, J=8.0), 
3.250(s,3H), 2.349(s,3H).
 13
C-NMR (100MHz, DMSO-d6) δ: 164.659，  139.127， 
133.491，132.981(2C), 132.952, 129.029,(2C), 128.964, 125.616, 123.066, 119.386, 
118.748, 114.483,43.585,18.188. DUIS-MS calculated for C16H15N3O3S, [M-H]-: 328.08, 
found 328.0,  Purity: 97.3%. 
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Figure 4.8 The Chemical construction of  4-cyano-N-(4- 
(methylsulfonamido)-3-methylphenyl)benzamide 
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 N-(4-(methylsulfonamido)-3-methylphenyl)-3-(trifluoromethyl)benzamide (3)  
Yield 62.7%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.447(s,1H), 9.008(s,1H), 
8.301(s,1H),  8.270(d,1H,J=8.0), 7.980, (d,1H,J=8.0) 7.799(t,1H,J=8.0), 7.679(s,1H), 
7.628(d,1H,J=8.8), 7.279(d,1H,J=8.8), 2.981(s,3H), 2.333(s,3H). 
13
C-NMR (100MHz, 
DMSO-d6) δ: 164.387, 137.523, 136.180, 135.468, 132.293, 131.706,  130.218,  
130.160,129.838,129.518,129.212(q,1C), 128.644(m,1C), 127.520, 
124.732,124.694,124.655,124.620(q,1C), 123.137, 119.159, 31.144, 18.840. DUIS-MS 
calculated for C16H15F3N2O3S, [M-H]-: 371.07, found 370.9,  Purity: 97.8%. 
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Figure 4.9 The Chemical construction of N-(4-(methyl 
sulfonamido)-3-methylphenyl)-3-(trifluoromethyl)benzamide 
 
 4-chloro-N-(4-(methylsulfonamido)-3-methylphenyl)-3-nitrobenzamide (4) 
Yield 61.7%. 
1
H-NMR (400MHz, DMSO-d6) δ: 10.733 (s,1H), 8.694(s,1H), 
8.375(s,1H), 8.316(d,1H, J=8.4),  7.790(d,1H,J=8.4), 7.757(s,1H), 7.750 (d,1H,J=8.8), 
7.353(d,1H,J=8.8), 3.270(s, 3H), 2.363(s,3H). 
13
C-NMR (100MHz, DMSO-d6) δ: 
162.997, 147.960, 139.503, 135.091, 133.599, 133.379, 132.566, 132.477, 128.694, 
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125.771, 125.377, 123.150, 119.449, 43.609. 18.230. DUIS-MS calculated for 
C15H14ClN3O2S, [M-H]-: 382.03, found381.9; Purity: 98.2%. 
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Figure 4.10 The Chemical construction of 4-chloro-N-(4- 
(methylsulfonamido)-3-methylphenyl)-3-nitrobenzamide 
 
 N-(4-(methylsulfonamido)-3-methylphenyl)-3,5-bis(trifluoromethyl)benzamide 
(5) 
Yield 55.4%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.593(s,1H), 9.573(s,1H), 
8.619(s,2H), 8.379 (s,1H), 7.640(s,1H) ， 7.741(d,1H,J=8.6),7.582 (d,1H,J=8.6), 
3.326(s,3H) ,2.256(s,3H), 
13
C-NMR (100MHz, DMSO-d6) δ: 160.290, 137.568, 135.467, 
132.523, 131.474,131.147,130.812,130.430(q,1C), 128.964(m,2C), 125.511(m,1C), 
124.975, 123.780, 123.086, 122.264, 119.028, 40.074，18.514 . DUIS-MS calculated for 
C17H14F6N2O3S, [M-H]-: 439.06, found 439.0, Purity: 98.8%. 
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Figure 4.11 The Chemical construction of N-(4-(methyl 
sulfonamido)-3-methylphenyl)-3,5-bis(trifluoromethyl)benzamide 
 
 4-chloro-N-(4-(ethylsulfonamido)-3-methylphenyl)-benzamide (6) 
Yield 68.9%. 
1
H-NMR (400MHz, DMSO-d6) δ: 10.295(s,1H), 8.985(s,1H), 7.985 
(d,2H,J=8.8), 7.662(d,1H,J=2.4), 7.618(d,2H,J=8.8), 7.583(dd,1H, J1=2.4, J2=8.8), 
7.233(d,1H,J=8.8), 3.075(q, 2H,J=8.0), 2.324(S,3H), 1.275(t,3H, J=8.0). 
13
C-NMR 
(100MHz, DMSO-d6) δ:  164.779, 137.547, 136.895, 135.290, 134.012, 131.542， 
130.064(2C), 128.940(2C), 127.299, 122.992, 119.043, 46.672, 18.917, 8.560 . DUIS-MS 
calculated for C1 6H17ClN2O3S, [M-H]-: 351.06 , found 351.0; Purity: 96.7%. 
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Figure 4.12 The Chemical construction of 4-chloro-N-(4- 
(ethylsulfonamido)-3-methylphenyl)-benzamide 
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 4-cyano-N-(4-(ethylsulfonamido)-3-methylphenyl)benzamide (7) 
Yield 60.7%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.449 (s, 1H), 8.999 
(s,1H),  8.106 (d,2H, J=8.4), 8.035 (d,2H, J=8.4), 7.668 (d,1H, J=2.4), 7.588 (dd,1H, 
J1= 2.4, J2= 8.4,), 7.250 (d,1H, J=8.4), 3.079 (q,2H, J=7.6), 2.328 (s,3H), 1.274 (t,3H, 
J=7.6). 
13
C-NMR (100MHz, DMSO-d6) δ: 164.493, 139.338, 137.279, 135.285, 
132.949, 131.817, 128.872, 127.274, 123.027, 119.091, 118.779, 114.342, 46.702, 
18.914, 8.561. DUIS-MS calculated for C17H17N3O3S, [M-H]-: 342.09,  found  
341.8,  Purity: 96.8%. 
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Figure 4.13 The Chemical construction of 4-cyano-N-(4-(ethyl 
sulfonamido)-3-methylphenyl)benzamide 
 
 N-(4-(ethylsulfonamido)-3-methylphenyl)-3-(trifluoromethyl)benzamide (8) 
Yield 61.7%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.433(s,1H), 8.990(s,1H),  
8.300(s,1H), 8.269(d,1H,J=7.6), 7.980 (d,1H,J=7.6), 7.799(t,1H,J=7.6), 7.667(s,1H), 
7.610 (d,1H,J=8.4), 7.259(d,1H,J=8.4), 3.087(q,2H,J=7.2), 2.339(s,3H), 1.282 
(t,3H,J=7.2). 
13
C-NMR (100MHz, DMSO-d6) δ: 164.373, 137.352, 136.191, 135.288, 
132.287, 131.763, 130.214, 130.162,129.842,129.524,129.183(q,1C),  128.628(m,1C), 
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127.273, 124.690(m,1C), 123.139,  119.171,  46.733, 18.995, 8.555. DUIS-MS 
calculated for C17H17F3N2O3S, [M-H]-: 385.08, found 384.8,  Purity: 97.5%. 
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Figure 4.14 The Chemical construction of N-(4-(ethylsulfonamido)-3- 
methylphenyl)-3-(trifluoromethyl)benzamide 
 
 4-chloro-N-(4-(ethylsulfonamido)-3-methylphenyl)-3-nitrobenzamide (9) 
Yield 64.3%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.516 (s,1H), 9.015 (s,1H), 
8.632 (d,1H, J=2.0), 8.258 (dd,1H, J=8.4, 2.0), 7.981(d,1H, J=8.4), 7.645 (d,1H, J=2.0), 
7.586(dd,1H, J1=2.0, J2=8.6), 7.260 (d,1H, J=8.6), 3.083 (q,2H, J=7.3),2.331(s,3H),  
1.274 (t,3H, J=7.3). 
13
C-NMR (100MHz, DMSO-d6) δ: 162.913, 137.060, 135.315, 
135.279, 133.299, 132.452, 131.961, 128.564, 127.292, 125.274, 123.091, 119.147, 
117.059, 46.743, 18.998, 8.554. DUIS-MS calculated for C16H16ClN3O5S, [M-H]-: 
396.04, found 396.0 Purity: 98.8%. 
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Figure 4.15 The Chemical construction of  4-chloro-N-(4-(ethyl 
sulfonamido)-3-methylphenyl)-3-nitrobenzamide 
 
 N-(4-(ethylsulfonamido)-3-methylphenyl)-3,5-bis(trifluoromethyl)benzamide 
(10) 
Yield 54.6%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.633(s,1H), 9.015(s,1H), 
8.621(s,2H), 8.377(s,1H), 7.658 (s,1H), 7.625(d,1H,J=8.4), 7.285(d,1H,J=8.4), 3.081 
(q,2H,J=7.2), 2.347(s,3H), 1.285, (t,3H,J=7.2). 
13
C-NMR (100MHz, DMSO-d6) δ: 
162.948, 137.509, 136.979, 135.287, 132.094, 131.490,131.156,130.824,130.490(q,1C), 
129.018(m,2C), 127.242, 125.564(m,1C), 123.261, 119.290, 46.786, 18.881, 8.556. 
DUIS-MS calculated for C18H16F6N2O3S, [M-H]-: 453.07,  found 453.0,  Purity: 
98.8%. 
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Figure 4.16 The Chemical construction of N-(4-(ethylsulfonamido)-3- 
methylphenyl)-3,5-bis(trifluoromethyl)benzamide 
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 4-Chloro-N-(3-methyl-4-trifluoromethanesulfonylamino-phenyl)-benzamide 
(11) 
Yield 59.7%. 
1
H-NMR (400MHz, DMSO-d6) δ: 11.341(s,1H), 10.367(s,1H), 
7.987 (d,2H,J=8.4), 7.740(s,1H), 7.636(m,3H), 7.299(d,1H,J=8.8), 2.320(s,3H). 
13
C-NMR (100MHz, DMSO-d6) δ: 164.98, 139.21, 137.02, 136.34, 133.89, 
130.10,(2C) , 128.96(2C), 128.91, 128.38, 122.90, 121.80, 119.19. DUIS-MS 
calculated for C15H12ClF3N2O3S, [M-H]-: 391.01, found  390.9,  Purity: 95.7%. 
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Figure 4.17 The Chemical construction of 4-Chloro-N-(3- 
methyl-4-trifluoromethanesulfonylamino-phenyl)-benzamide 
 
 4-Cyano-N-(3-methyl-4-trifluoromethanesulfonylamino-phenyl)-benzamide (12) 
Yield 52.7%. 
1
H-NMR (400MHz, DMSO-d6) δ:   11.398(s, 1H), 10.543 (s, 1H), 
8.106 (d, 2H, J=8.0), 8.041(d, 2H, J=8.0),  7.752( s, 1H)， 7.654(d, 2H, J=8.8), 7.248 (d, 
1H, J=8.8), 2.326 (s, 3H). 
13
C-NMR (100MHz, DMSO-d6) δ: 164.720, 139.211, 138.969, 
136.400, 132.867(2C), 129.013(2C), 128.965, 128.636, 122.942, 119.426, 118.750, 
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114.454, 18.342. DUIS-MS calculated for C16H12F3N3O3S, [M-H]-: 382.05, found  
381.9,  Purity: 97.9%. 
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Figure 4.18 The Chemical construction of  4-Cyano-N-(3- 
methyl-4-trifluoromethanesulfonylamino-phenyl)-benzamide 
 
 N-(3-Methyl-4-trifluoromethanesulfonylamino-phenyl)-3-trifluoromethyl-benza
mide (13) 
Yield 55.4%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.550 (s,1H), 8.274 (s,1H), 
8.246 (d, 1H, J= 8.0), 7.973 (d, 1H, J=8.0), 7.791 (t, 1H, J=8.0), 7.721 (s, 1H), 7.656 
(d,1H, J=8.4), 7.241 (d, 1H, J=8.4), 2.321 (s,3H) . 
13
C-NMR (100MHz, DMSO-d6) δ: 
164.716, 138.999, 136.502, 135.978, 132.282, 130.288, 
130.197,129.877,129.557,129.241(q,1C), 129.001, 128.771(m,1C), 128.512, 
124.703(m,1C), 123.111, 119.372, 18.290. DUIS-MS calculated for C16H12F6N2O3S, 
[M-H]-: 425.04,  found  424.8,  Purity: 98.7%. 
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Figure 4.19 The Chemical construction of N-(3-Methyl-4-trifluoromethane 
sulfonylamino-phenyl)-3-trifluoromethyl-benzamide 
 
 4-Chloro-N-(3-methyl-4-trifluoromethanesulfonylamino-phenyl)-3-nitro-benza
mide (14) 
Yield 52.9%. 
1
H-NMR (400MHz, DMSO-d6) δ:  11.382(s,1H), 10.633 (s,1H), 
8.645 (s,1H), 8.272 (d,1H, J=8.4), 7.985 (d,1H, J=8.4), 7.738 (s, 1H), 7.664 (d, 1H, 
J=8.6), 7.259 (d, 1H, J=8.6), 2. 332 (s,3H) . 
13
C-NMR (100MHz, DMSO-d6) δ: 163.025, 
147.858, 138.814, 136.456, 135.153, 133.340, 132.465, 129.014, 128.716, 128.671, 
125.341, 123.008, 119.301, 18.339. DUIS-MS calculated for C15H11ClF3N3O5S, [M-H]-: 
436.00, found 435.9,  Purity: 96.8%. 
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Figure 4.20 The Chemical construction of 4-Chloro-N-(3- 
methyl-4-trifluoromethanesulfonylamino-phenyl)-3-nitro-benzamide 
 
 107 
 
 N-(3-Methyl-4-trifluoromethanesulfonylamino-phenyl)-3,5-bis-trifluoromethyl-
benzamide (15) 
Yield 53.6%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.693 (s, 1H), 8.611 (s,2H), 
8.462(s,1H), 8.391 (s,1H), 7.724 (s, 1H), 7.673 (d,1H,J=8.8), 7.275 (d,1H, J=8.8), 2.338 
(s, 3H). NMR (100MHz, DMSO-d6) δ: 163.073, 138.647, 137.409, 136.417, 
131.498,131.167,130.837,130.505(q,2C), 129.017(m,2C), 128.965, 125.719(m,1C), 
127.660,124.946,122.232,119.517(q,2CF3), 123.163, 121.898, 119.406, 18.319. 
DUIS-MS calculated for C17H11F9N2O3S, [M-H]-: 493.03, found  492.8,  Purity: 
98.1%.   
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Figure 4.21 The Chemical construction of N-(3-Methyl-4-trifluoro 
methanesulfonylamino-phenyl)-3,5-bis-trifluoromethyl-benzamide 
 
 4-chloro-N-(4-(methylsulfonamido)-3-methoxylphenyl)benzamide (16) 
Yield 69.8%. 
1
H-NMR (400MHz, DMSO-d6) δ: 10.339 (s,1H), 8.837 (s,1H), 
7.997 （ d,2H,J=8.4 ） ,7.627 （ d,2H,J=8.4 ） , 7.622(s,1H), 7.353 (d,1H,J=8.8), 
7.217(d,1H,J=8.8), 3.836(s,3H), 2.929(s,3H). 
13
C-NMR (100MHz, DMSO-d6) δ: 164.83， 
153.563， 139.435， 136.595， 134.001，130.056（2C） 129.922（2C）， 127.373， 
121.532，  112.756，  104.901，  56.151 , 40.062.  DUIS-MS calculated for 
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C15H15CllN2O4S, [M-H]-: 353.04 , found 352.9; Purity: 96.7%. 
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Figure 4.22 The Chemical construction of 4-chloro-N-(4- 
(methylsulfonamido)-3-methoxylphenyl)benzamide 
 
 4-cyano-N-(4-(methylsulfonamido)-3-methoxylphenyl)benzamide (17) 
Yield 65.3%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.511 (s, 1H), 8.865 (s,1H), 
8.116 (d,2H,J=8.4), 8.045 (d,2H, J=8.4), 7.623 ( d, 1H,J=2.0), 7.336 (dd,1H, J1= 2.0, J2= 
8.8),  7.233 (d,1H, J=8.8), 3.838 (s,3H), 2.933 (s,3H). 
13
C-NMR (100MHz, DMSO-d6) 
δ:164.56, 153.53, 139.31, 138.29, 132.96, 128.96, 127.33, 121.99, 118.77, 114.40, 112.81, 
104.91, 56.16, 40.07.  DUIS-MS calculated for C16H15N3O4S, [M-H]-: 344.07, found 
344.0,  Purity: 98.0%. 
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Figure 4.23  The Chemical construction of 4-cyano-N-(4- 
(methylsulfonamido)-3-methoxylphenyl)benzamide 
 
 N-(4-(methylsulfonamido)-3-methoxylphenyl)-3-(trifluoromethyl) benzamide 
(18) 
yield 65.3%. 
1
H-NMR (400MHz, DMSO-d6) δ:    10.499 (s, 1H), 8.856 (s,1H), 
8.303 (s,1H), 8.279 (d, 1H, J=7.6), 7.989 (d, 1H, J= 7.6), 7.808 (t,1H, J=7.6), 7.618 (s, 
1H), 7.374 (d, 1H, J=8.8), 7.241 (d, 1H, J=8.8), 3.848 (s, 3H), 2.939 (s, 3H). 
13
C-NMR 
(100MHz, DMSO-d6) δ:  164.463, 153.535, 138.351, 136.179，132.281，130.233，
130.180,129.859,129.539,129.219(q,1C),  128.655(m,1C), 127.288, 124.692(m,1C),  
121.962, 112.922, 105.051, 56.187, 40.070. DUIS-MS calculated for C16H15F3N2O4S, 
[M-H]-: 387.06, found 386.9,  Purity: 97.0%. 
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Figure 4.24 The Chemical construction of N-(4-(methyl 
sulfonamido)-3-methoxylphenyl)-3-(trifluoromethyl) benzamide 
 
 4-chloro-N-(4-(methylsulfonamido)-3-methoxylphenyl)-3-nitrobenzamide (19) 
Yield 70.1%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.572 (s, 1H), 8.876 (s, 1H), 
8.645 (s,1H), 8.275 (d, 1H, J=8.4), 7.994 (d, 1H, J=8.4), 7.589 (s, 1H), 7.358 
(d,1H,J=8.4), 7.247 (d, 1H,J=8.4), 3.844 (s,3H), 2.940 (s,3H). 
13
C-NMR (100MHz, 
DMSO-d6) δ: 162.972, 153.502, 147.974, 138.041, 135.272, 133.279, 132.466, 128.602, 
127.255, 125.262, 122.195, 112.916, 106.007, 56.196, 40.064. DUIS-MS calculated for 
C15H14ClN3O6S, [M-H]-:398.02, found 397.9; Purity: 98.3 %. 
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Figure 4.25 The Chemical construction of 4-chloro-N-(4- 
(methylsulfonamido)-3-methoxylphenyl)-3-nitrobenzamide 
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 N-(4-(methylsulfonamido)-3-methoxylphenyl)-3,5-bis(trifluoromethyl) 
benzamide (20) 
Yield 63.4%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.694 (s,1H), 8.901 (s,1H), 
8.621 (s,2H), 8.394 (s,1H), 7.589 (d, 1H, J=2.0), 7.373 (dd,1H, J1= 2.0, J2= 8.8), 7.266 (d, 
1H,J=8.8), 3.854 (s, 3H), 2.948 (s,3H). 
13
C-NMR (100MHz, DMSO-d6) δ: 162.952, 
153.483, 137.924, 137.486, 131.488,131.159,130.829,130.495(q,2C)，129.017(m,2C), 
127.209, 125.631(m,1C), 127.675,124.959,122.245,199.531(q,2CF3), 122.311, 113.082, 
105.149, 56.214, 40.039. DUIS-MS calculated for C17H14F6N2O4S, [M-H]-: 455.05, 
found 454.9,  Purity: 96.1%. 
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Figure 4.26 The Chemical construction of N-(4-(methylsulfonamido) 
-3-methoxylphenyl)-3,5-bis(trifluoromethyl) benzamide 
 
 4-chloro-N-(4-(ethylsulfonamido)-3-methoxylphenyl)benzamide (21) 
Yield 69.9%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.345(s,1H), 8.843(s,1H), 
7.994 (d,2H,J=8.4), 7.628(d, 2H,J=8.4), 7.608(d, 1H,J=2.0), 7.337 (dd,1H, J1= 2.0, J2= 
8.4) ,7.225(d,1H,J=8.4), 3.824(s,3H), 2.992(q,2H, J=7.2), 1.257 (t,3H,J=7.2). 
13
C-NMR 
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(100MHz, DMSO-d6) δ: 164.932， 153.380， 138.439， 136.950， 133.996， 130.059， 
128.962， 127.245， 121.733， 112.736， 104.803， 56.108， 46.606， 8.482.  
DUIS-MS calculated for C16H17ClN2O4S, [M-H]-: 367.05, found366.9,  Purity: 97.5%. 
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Figure 4.27 The Chemical construction of 4-chloro-N-(4- 
(ethylsulfonamido)-3-methoxylphenyl)benzamide 
 
 4-Cyano-N-(4-ethanesulfonylamino-3-methoxy-phenyl)-benzamide  (22) 
Yield 65.8%. 
1
H-NMR (400MHz, DMSO-d6) δ:    10.503 (s,1H), 8.856 (s,1H), 
8.114 (d,2H, J=8.4), 8.045 (d,2H,J=8.4), 7.607(d.1H, J=2.0), 7.339(dd,1H, J1= 2.0, J2= 
8.4), 7.243 (d,1H, J=8.4), 3.828 (s,3H), 2.999 (q,2H,J=7.2), 1.258 (t,3H,J=7.2) . 
13
C-NMR (100MHz, DMSO-d6) δ: 164.54, 153.32, 139.32, 138.13, 132.95, 128.96, 
127.11, 122.07, 118.76, 114.40, 112.83, 104.87, 56.14, 46.65, 8.47.  DUIS-MS 
calculated for C17H17N3O4S, [M-H]-: 358.09, found  357.9,  Purity: 96.9%. 
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Figure 4.28 The Chemical construction of 4-Cyano-N-(4-ethane 
sulfonylamino-3-methoxy-phenyl)-benzamide 
 
 N-(4-(ethylsulfonamido)-3-methoxylphenyl)-3-(trifluoromethyl)benzamide(23)  
Yield 62.3%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.495(s,1H), 8.853(s,1H), 
8.301(s,1H), 7.276(d,1H,J=7.6), 7.988(d,1H,J=7.6), 7.806(t,1H,J=7.6), 7.603(s,1H), 
7.358(d,1H,J=8.8), 7.252 (d,1H,J=8.8), 3.838(s,3H), 3.006(q,2H,J=7.2), 
1.264(t,3H,J=7.2). 
13
C-NMR (100MHz, DMSO-d6) δ: 164.442, 153.344, 138.199, 
136.181, 132.276, 130.228, 130.183,129.855,129.534,129.218(q,1C), 128.677(m,1C), 
127.135, 128.524,125.813,123.102,120.379(q,CF3), 124.649(m,1C)， 121.997， 112.910， 
104.968， 56.151， 46.654， 8.481.  DUIS-MS calculated for C17H17F3N2O4S, [M-H]-: 
401.08,  found 400.9,  Purity: 97.8%. 
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Figure 4.29 The Chemical construction of  N-(4-(ethylsulfonamido) 
-3-methoxylphenyl)-3-(trifluoromethyl)benzamide 
 
 4-chloro-N-(4-(ethylsulfonamido)-3-methoxylphenyl)-3-nitrobenzamide (24) 
Yield 69.7.4%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.561(s,1H), 8.858(s,1H), 
8.639 (d,1H, J=2.0), 8.268 (dd,1H,J=8.4,2.0), 7.992(d,1H,J=8.4), 7.570(d,1H,J=1.6), 
7.339(dd,1H, J1=1.6 J2=8.8,), 7.256 (s,1H,J=8.8), 3.834(s,3H), 3.006(q,2H,J=7.2), 
1.260(t,3H,J=7.2). 
13
C-NMR (100MHz, DMSO-d6) δ: 162.856, 152.327 , 147.865, 
137.902, 135.267, 133.276, 132.466, 128.600, 127.149, 125.265, 122.203, 
112.899,104.897, 56.153, 45.667, 8.484. DUIS-MS calculated for C16H16ClN3O6S, 
[M-H]-: 412.04, found 411.9,  Purity: 96.7%. 
 
O
H
N
N+
O
-O O
S
O
O
N
H
Cl
 
Figure 4.30  The Chemical construction of 4-chloro-N-(4-(ethyl 
sulfonamido)-3-methoxylphenyl)-3-nitrobenzamide 
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 N-(4-(ethylsulfonamido)-3-methoxylphenyl)-3,5-bis(trifluoromethyl)benzamide 
(25) 
Yield 62.4%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.684 (s,1H), 8.883 (s,1H), 
8.618 (s,2H), 8.397 (s,1H), 7.573 (d ,1H, J=2.0), 7.354 (q, 1H, J1=2.0, J2= 8.6), 7.275 (d, 
1H, J=8.6), 3.844 (s,3H), 3.013 (q,2H, J=7.3), 1.263 (t,3H, J=7.3). 
13
C-NMR (100MHz, 
DMSO-d6) δ: 162.932, 153.296, 137.773, 137.512, 
131.497,131.168,130.836,130.506(q,2C), 129.006(m,2C), 
127.675,124.962,122.250,119.532(q,2CF3), 127.030, 125.669(m,1C), 122.382, 113.094, 
105.107, 56.196, 46.715, 8.481. DUIS-MS calculated for C18H16F6N2O4S, [M-H]-: 
469.07,  found 468.9,  Purity: 98.2%. 
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Figure 4.31 The Chemical construction of N-(4-(ethylsulfonamido)-3- 
methoxylphenyl)-3,5-bis(trifluoromethyl)benzamide 
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 4-Chloro-N-(3-methoxy-4-trifluoromethanesulfonylamino-phenyl)-benzamide 
(26) 
Yield 45.5%. 
1
H-NMR (400MHz, DMSO-d6) δ:   11.141(s,1H),10.439 (s, 1H), 
7.999 (d, 2H, J=8.4), 7.662 (s, 1H), 7.635 (d, 2H, J=8.4), 7.402 (d,1H, J=8.4), 7.223 
(d,1H, J=8.4), 3.836 (s,3H). 
13
C-NMR (100MHz, DMSO-d6) δ:  165.061, 155.451, 
140.658, 137.086, 133.862, 130.110,(2C), 129.724, 128.992(2C), 118.028, 
112.583,104.755, 56.230.  DUIS-MS calculated for C15H12ClF3N2O4S, [M-H]-: 407.01, 
found  406.9,  Purity: 97.4%. 
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Figure 4.32 The Chemical construction of  4-Chloro-N- 
(3-methoxy-4-trifluoromethanesulfonylamino-phenyl)-benzamide 
 
 4-Cyano-N-(3-methoxy-4-trifluoromethanesulfonylamino-phenyl)-benzamide 
(27) 
Yield 45.0 %. 
1
H-NMR (400MHz, DMSO-d6) δ:   11.219(s,1H), 10.595(s,1H)， 
8.115(d,2H, J=8.4), 8.052(d,2H,J=8.4), 7.659(d,1H, J=1.6)， 7.400(dd,1H, J1= 1.6, J2= 
8.4), 7.241(d,1H, J=8.4), 3.840(s, 3H). 
13
C-NMR (100MHz, DMSO-d6) δ: 164.797, 
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155.459, 140.410, 139.185, 132.987(2C), 129.775, 129.009(2C), 118.747, 114.507, 
112.656, 107.673, 104.788, 56.254. DUIS-MS calculated for C16H12F3N3O4S, [M-H]-: 
398.04, found  397.9,  Purity: 96.2%. 
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Figure 4.33  The Chemical construction of 4-Cyano-N-(3- 
methoxy-4-trifluoromethanesulfonylamino-phenyl)-benzamide 
 
 N-(3-Methoxy-4-trifluoromethanesulfonylamino-phenyl)-3-trifluoromethyl-benz
amide (28) 
Yield 45.8%. 
1
H-NMR (400MHz, DMSO-d6) δ:   11.208(s,1H), 10.578(s,1H), 
8.300(s,1H), 8.277(d,1H, J=7.6), 7.998(d,1H, J=7.6), 7.815(t,1H, J=7.6), 7.652(s,1H), 
7.419(d,1H, J=8.4), 7.247(d,1H, J=8.4), 3.337(s, 1H). 
13
C-NMR (100MHz, DMSO-d6) δ:  
164.691, 155.474, 140.490, 138.515, 136.072, 132.033, 131.067, 
130.780,130.269,129.744,129.240(q,1C), 128.852,  128.472(m,1C), 124.739(m,1C), 
112.747, 104.912, 56.273. DUIS-MS calculated for C16H12F6N2O4S, [M-H]-: 441.03,  
found  440.9,  Purity: 98.7%. 
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Figure 4.34 The Chemical construction of N-(3-Methoxy-4-trifluoro 
methanesulfonylamino-phenyl)-3-trifluoromethyl-benzamide 
 
 4-Chloro-N-(3-methoxy-4-trifluoromethanesulfonylamino-phenyl)-3-nitro-benzamid
e (29) 
Yield 50.7%. 
1
H-NMR (400MHz, DMSO-d6) δ:  11.219(s,1H), 10.657(s,1H), 
8.647(s,1H), 8.276(d,1H, J=8.0), 7.999(d,1H, J=8.0), 7.628(s,1H), 7.407(d,1H, J=8.4), 
7.257(d,1H, J=8.4), 56.291(s,3H). 
13
C-NMR (100MHz, DMSO-d6) δ:163.107, 155.466, 
147.879, 140.188, 135.157,  133.322, 132.491, 129.761, 128.721, 125.318,  118.479, 
112.755, 104.900, 56.291. C15H11ClF3N3O6S, [M-H]-: 452.01, found  451.9,  Purity: 
97.8% 
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Figure 4.35 The Chemical construction of 4-Chloro-N-(3- 
methoxy-4-trifluoromethanesulfonylamino-phenyl)-3-nitro-benzamide 
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 N-(3-Methoxy-4-trifluoromethanesulfonylamino-phenyl)-3,5-bis-trifluoromethyl
-benzamide (30) 
Yield 52.7%. 
1
H-NMR (400MHz, DMSO-d6) δ:  11.249(s,1H), 10.769(s,1H), 
8.618(s,2H), 8.395(s,1H), 7.630(s,1H), 7.422(d,1H, J=8.6), 7.276(d,1H, J=8.6), 
3.860(s,3H).  
13
C-NMR (100MHz, DMSO-d6) δ: 163.194, 155.471, 140.141, 137.404, 
131.508,131.179,130.947,130.516(q,2C), 129.789, 129.066(m,2C), 125.700(m,1C)，
127.656,124.939,122.226,119.515(q,2CF3), 118.529，112.900，  105.016，  56.302.  
DUIS-MS calculated for C17H11F9N2O4S, [M-H]-: 509.03,  found  508.9,  Purity: 
97.7%. 
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Figure 4.36 The Chemical construction of N-(3-Methoxy-4-trifluoro 
methanesulfonylamino-phenyl)-3,5-bis-trifluoromethyl-benzamide 
 
 4-chloro-N-(3-chloro-4-(methylsulfonamido)phenyl)benzamide  (31) 
Yield 56.7%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.492(s,1H), 9.409(s,1H), 
8.062(s,1H), 7.994 (d,2H, J=8.4), 7.710(d,1H,J=8.4), 7.639(d,2H,J=8.4), 
7.444(d,1HJ=8.4), 3.032(S,3H). 
13
C-NMR (100MHz, DMSO-d6) δ: 165.095, 138.749, 
137.200, 133.623, 130.143(2C), 130.093, 129.765, 129.221, 129.033(2C), 212.422, 
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119.971, 41.305.  DUIS-MS calculated for C14H12Cl2N2O3S, [M-H]-:356.99, found 
356.8; Purity: 98.9%. 
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Figure 4.37 The Chemical construction of 4-chloro-N- 
(3-chloro-4-(methylsulfonamido)phenyl)benzamide 
 
 4-cyano-N-(3-chloro-4-(methylsulfonamido)phenyl)benzamide  (32) 
Yield 66.8%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.662 (s, 1H), 9.434 (s,1H), 
8.116 (d, 2H, J=8.4), 8.066(s,1H), 8.056 (d,2H,J=8.4), 7.712 (d,1H,J=8.4), 7.461 (d,1H, 
J=8.4), 3.037 (s, 3H) .
 13
C-NMR (100MHz, DMSO-d6) δ:  164.824, 138.938, 138.462, 
133.011(2C), 130.051, 129.187, 129.044(2C), 121.509, 120.054, 118.721, 114.594, 
99.985, 41.323. DUIS-MS calculated for C15H12ClN3O3S, [M-H]-: 348.02, found 347.9,  
Purity: 98.7%. 
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Figure 4.38 The Chemical construction of 4-cyano-N-(3- 
chloro-4-(methylsulfonamido)phenyl)benzamide 
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 N-(3-chloro-4-(methylsulfonamido)phenyl)-3-(trifluoromethyl)benzamide (33) 
Yield 69,8%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.842(s,1H), 9.451(s,1H), 
8.343(s,1H), 8.113(s,1H), 7.994 (d,1H,J=6.8), 7.803(m,3H), 7.459(d,1H,J=8.4), 
3.039(s,3H).  
13
C-NMR (100MHz, DMSO-d6) δ: 164.708, 138.724, 135.710, 132.546, 
130.193, 130.161,129.842,129.523,129.210(q,1C), 130.130,129.928, 129.106, 
128.846(m,1C), 125.004(m,1H), 121.759, 120.242, 41.287. DUIS-MS calculated for 
C15H12ClF3N2O3S, [M-H]-: 391.01, found 390.9,  Purity: 98.7%. 
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Figure 4.39 The Chemical construction of N-(3-chloro-4-(methyl 
sulfonamido)phenyl)-3-(trifluoromethyl)benzamide 
 
 4-chloro-N-(3-chloro-4-(methylsulfonamido)phenyl)-3-nitrobenzamide (34) 
Yield 68.8%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.716(s,1H), 9.450(s,1H), 
8.645(s,1H), 8.268 (d,1H, J=8.4), 8.045(s,1H), 8.001(d,1H,J=8.4), 7.704(d,1H,J=8.8), 
7.473(d,1H,J=8.8), 3.041(s,3H). 
13
C-NMR (100MHz, DMSO-d6) δ: 163.134, 147.875, 
138.237, 134.910, 133.350, 132.534, 130.207, 130.029, 129.161, 128.934, 125.354, 
121.599, 120.116, 41.344. DUIS-MS calculated for C14H11Cl2N3O5S, [M-H]-:401.97, 
found 401.8; Purity: 98.6%. 
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Figure 4.40 The Chemical construction of 4-chloro-N-(3- 
chloro-4-(methylsulfonamido)phenyl)-3-nitrobenzamide 
 
 N-(3-chloro-4-(methylsulfonamido)phenyl)-3,5-bis(trifluoromethyl)benzamide 
(35) 
Yield 51.2%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.803(s,1H),  9.445(s,1H),  
8.618(s,2H),  8.402(s,1H), 8.051(s,1H),  7.727(d,1H,J=8.8), 7.495(d,1H,J=8.8), 
3.052(s,3H). 
13
C-NMR (100MHz, DMSO-d6) δ:  163.210, 138.142, 137.200, 
131.539,131.214,130.879,130.551,(q,2C) 130.334, 130.004, 129.105, 129.067(m,2C), 
127.643,124.934,122.225,119.509(q,2CF3), 125.830(m,1C), 121.803, 120.260, 40.077. 
DUIS-MS calculated for C16H11ClF6N2O3S, [M-H]-: 459.00, found 458.8,  Purity: 
99.2%. 
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Figure 4.41 The Chemical construction of N-(3-chloro-4-(methyl 
sulfonamido)phenyl)-3,5-bis(trifluoromethyl)benzamide 
 
 4-chloro-N-(3-chloro-4-(ethylsulfonamido)phenyl)benzamide  (36) 
Yield 66.3%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.477(s,1H), 9.382(s,1H), 
8.050(s,1H), 7.992 (d,2H, J=8.0), 7.693(d,1H,J=8.6), 7.634(d,2H,J=8.0), 
7.447(d,1H,J=8.6), 3.121(q,2H,J=7.2), 1.295 (t,3H,J=7.2). 
13
C-NMR (100MHz, 
DMSO-d6) δ:  165.074, 138.571, 137.191, 133.632, 130.136, 129.874, 129.827, 129.020, 
121.399, 119.964, 99.992, 47.608, 8.564. DUIS-MS calculated for C15H14Cl2N2O3S, 
[M-H]-: 371.00, found 370.9,  Purity: 98.1%. 
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Figure 4.42 The Chemical construction of 4-chloro-N- 
(3-chloro-4-(ethylsulfonamido)phenyl)benzamide 
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 4-cyano-N-(3-chloro-4-(ethylsulfonamido)phenyl)benzamide (37) 
Yield 62.7%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.649(s,1H), 9.412(s,1H), 
8.058(s,1H), 8.113(d,2H, J=8.0), 8.048(d,2H,J=8.0), 7.694 (d,1H, J=8.6), 7.463 (d,1H, 
J=8.6), 3.125(q,2H,J=7.2), 1.294 (t,3H,J=7.2). 
13
C-NMR (100MHz, DMSO-d6) δ: 
164.801, 138.943, 138.283, 133.000(2C), 130.162, 129.787, 129.039(2C), 128.976, 
121.475, 120.047, 118.720, 114.599, 47.631, 8.562. DUIS-MS calculated for 
C16H14ClN3O3S, [M-H]-: 362.04, found  361.9,  Purity: 97.8%. 
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Figure 4.43 The Chemical construction of 4-cyano-N-(3- 
chloro-4-(ethylsulfonamido)phenyl)benzamide 
 
 N-(3-chloro-4-(ethylsulfonamido)phenyl)-3-(trifluoromethyl)benzamide (38) 
Yield 62.5%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.661 (s,1H), 9.410 (s,1H), 
8.309 (s, 1H), 8.283 (d,1H, J=7.4), 8.061 (s, 1H), 7.997 (d,1H, J=7.4), 7.811 (t,1H, J=7.4), 
7.719 (d,1H, J=8.6), 7.467 (d, 1H, J=8.6), 3.130 (q, 2H, J=7.2), 1.299 (t, 3H ,J=7.2) . 
13
C-NMR (100MHz, DMSO-d6) δ: 164.678, 138.382, 135.818, 132.381, 130.285, 
130.082, 130.211,129.892,129.571,129.251(q,1C), 129.800, 128.970, 128.879(m,1C), 
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128.487,125.781,123.073,120.360(q,CF3), 124.787(m), 121.579, 120.112，47.629，8.563. 
DUIS-MS calculated for C16H14ClF3N2O3S, [M-H]-: 405.03,  found  404.9,  Purity: 
99.1%. 
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Figure 4.44 The Chemical construction of N-(3-chloro-4-(ethyl 
sulfonamido)phenyl)-3-(trifluoromethyl)benzamide 
 
 4-chloro-N-(3-chloro-4-(ethylsulfonamido)phenyl)-3-nitrobenzamide (39) 
Yield 67.7%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.699(s,1H), 9.424(s,1H), 
8.642(s,1H), 8.266 (d,1H, J=8.4), 8.033(s,1H), 7.999 (d,1H,J=8.4), 7.686(d,1H,J=8.8), 
7.475(d,1H,J=8.8), 3.130(q,2H,J=7.2), 1.295 (t,3H,J=7.2). 
13
C-NMR (100MHz, 
DMSO-d6) δ: 163.11, 147.88, 138.06, 134.92, 133.34, 132.53, 130.31, 129.77, 128.97, 
128.82, 125.35, 121.55, 120.10, 47.65, 8.56. DUIS-MS calculated for C15H13Cl2N3O5S, 
[M-H]-: 415.99, found 415.8,  Purity: 98.8%. 
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Figure 4.45 The Chemical construction of 4-chloro-N- 
(3-chloro-4-(ethylsulfonamido)phenyl)-3-nitrobenzamide 
 N-(3-chloro-4-(ethylsulfonamido)phenyl)-3,5-bis(trifluoromethyl)benzamide 
(40) 
Yield 54.1%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.808(s,1H), 9.434 (s,1H), 
8.607 (s, 2H), 8.380 (s, 1H), 8.034 (s, 1H), 7.703 (d,1H, J=8.6), 7.488 (d, 1H, J=8.6), 
3.135 (q,2H, J=7.2), 1.299(t, 3H,J=7.2). 
13
C-NMR (100MHz, DMSO-d6) δ: 163.182, 
137.951, 137.164, 131.537,131.204,130.873,130.539(q,2C), 130.452, 129.730, 
129.062(m,2C), 128.886, 125.777(m,1C), 127.624, 124.911,122.198,119.483(q,2CF3), 
121.754, 120.242, 47.668, 8.532.  DUIS-MS calculated for C17H13ClF6N2O3S, [M-H]-: 
473.02,  found  472.9,  Purity: 97.2%. 
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Figure 4.46 The Chemical construction of N-(3-chloro-4-(ethyl 
sulfonamido)phenyl)-3,5-bis(trifluoromethyl)benzamide 
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 4-chloro-N-(3-chloro-4-(trifluoromethylsulfonamido)phenyl)benzamide (41) 
Yield 48.2%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.719(s,1H), 8.113 (d,2H, 
J=8.4), 8.102(s,1H), 8.056 (d,2H, J=8.4),7.745 (d,1H, J=8.8),7.457 (d,1H, J=8.8). 
13
C-NMR (100MHz, DMSO-d6) δ:164.960, 139.664, 138.866, 133.017(2C),131.734, 
130.443, 129.076(2C),  121.499, 120.081, 118.705, 114.657.  DUIS-MS calculated for 
C14H9Cl2F3N2O3S, [M-H]-: 410.96, found  410.8,  Purity: 98.2%. 
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Figure 4.47 The Chemical construction of 4-chloro-N-(3- 
chloro-4-(trifluoromethylsulfonamido)phenyl)benzamide 
 
 4-cyano-N-(3-chloro-4-(trifluoromethylsulfonamido)phenyl)benzamide (42) 
Yield 50.5%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.704 (s, 1H), 
8.112(d,2H,J=8.4), 8.082(d,1H,J=2.0), 8.055 (d,2H,J=8.4), 7.729(dd,1H,J=8.8,2.0), 7.450 
(d,1H,J=8.8). 
13
C-NMR (100MHz, DMSO-d6) δ:  164.924, 138.887, 137.632, 
133.018(2C), 131.546, 130.209, 125.353, 129.071(2C), 121.488, 120.060, 118.714, 
114.631. DUIS-MS calculated for C15H9ClF3N3O3S, [M-H]-: 401.99,  found  401.8,  
Purity: 97.2%. 
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Figure 4.48 The Chemical construction of 4-cyano-N-(3- 
chloro-4-(trifluoromethylsulfonamido)phenyl)benzamide 
 
 N-(3-chloro-4-(trifluoromethylsulfonamido)phenyl)-3-(trifluoromethyl)benzami
de (43) 
Yield 49.7%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.730 (s,1H), 8.307 (s,1H), 
8.279(d,1H, J=7.6), 8.110(s, 1H), 8.003 (d,1H,J=7.6), 7.814 (t,1H, J=7.6), 7.775 (d,1H, 
J=8.8), 7.463 (d,1H, J=8.8). 
13
C-NMR (100MHz, DMSO-d6) δ: 164.85, 139.87, 135.73, 
132.42, 131.80, 130.54, 130.31, 130.20,129.89,129.58,129.27(q,1C), 128.96(m,1C), 
124.83(m,1C), 128.47,125.76,123.05,120.34(q,CF3), 121.58, 120.13, 118.66. DUIS-MS 
calculated for C15H9ClF6N2O3S, [M-H]-: 444.98,  found  444.8,  Purity: 98.6%. 
 
O
N
H F
F
F
S
O
O H
NF
F
F
Cl
 
Figure 4.49 The Chemical construction of N-(3-chloro-4-(trifluoro 
methylsulfonamido)phenyl)-3-(trifluoromethyl)benzamide 
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 4-chloro-N-(3-chloro-4-(trifluoromethylsulfonamido)phenyl)-3-nitrobenzamide 
(44) 
Yield 49.7%. 
1
H-NMR (400MHz, DMSO-d6) δ: 10.791(s,1H), 8.645(s,1H), 8.268 
(d,1H, J=8.4), 8.081(s,1H), 8.100(d,1H,J=8.4), 7.744(d,1H,J=8.8), 7.470(d,1H,J=8.8), 
13
C-NMR (100MHz, DMSO-d6) δ:  163.291， 147.871， 139.510，134.831, 133.388, 
132.544, 131.783, 130.537, 128.907, 125.408, 121.885,  121.579, 120.144. DUIS-MS 
calculated for C14H8Cl2F3N3O5S, [M-H]-: 455.94, found 455.8,  Purity: 97.8%. 
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Figure 4.50 The Chemical construction of  4-chloro-N- 
(3-chloro-4-(trifluoromethylsulfonamido)phenyl)-3-nitrobenzamide 
 
 N-(3-chloro-4-(trifluoromethylsulfonamido)phenyl)-3,5-bis(trifluoromethyl) 
benzamide (45) 
Yield 48.8%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.851 (s,1H), 8.609 (s,2H), 
8.403 (s, 1H), 8.073 (s,1H), 7.746 (d,1H, J=8.8), 7.482 (d, 1H, J=-8.8) 
13
C-NMR 
(100MHz, DMSO-d6) δ: 163.344 ， 137.156, 131.625, 
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131.536,131.207,130.784,130.544(q,2C), 130.874, 130.312, 129.093(m,2C),  
125.874(m,1C), 127.632,124.921,122.206119.491(q,2CF3), 121.975, 121.751, 120.253. 
DUIS-MS calculated for C16H8ClF9N2O3S, [M-H]-: 512.97,  found  512.8,  Purity: 
97.3%. 
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Figure 4.51 The Chemical construction of N-(3-chloro-4-(trifluoro 
methylsulfonamido)phenyl)-3,5-bis(trifluoromethyl) benzamide 
 
 4-chloro-N-(3-fluoro-4-(methylsulfonamido)phenyl)benzamide  (46) 
Yield 52.7%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.573(s,1H)， 9.478(s,1H), 
7.990 (d,2H, J=8.0)，  7.843(d,1H,J=12.8), 7.636 (d,2H,J=8.0)， 7.538, (d,1H,J=8.6) , 
7.372(t,1H,J=8.6)，  3.011 (s,3H). 13C-NMR (100MHz, DMSO-d6) δ:  165.093, 
157.637,155.207(1C), 138.871,138.767(1C), 137.168, 133.687, 130.136(2C), 
129.021(2C), 128.429, 120.470,120.339(1C), 116.747,116.718(1C), 
108.451,108.200(1C), 40.067. DUIS-MS calculated for C14H12ClFN2O3S, [M-H]-:341.02, 
found 340.9; Purity: 96.8%. 
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Figure 4.52 The Chemical construction of 4-chloro-N-(3- 
fluoro-4-(methylsulfonamido)phenyl)benzamide 
 
 4-cyano-N-(3-fluoro-4-(methylsulfonamido)phenyl)benzamide  (47) 
Yield 48.9%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.680 (s,1H)， 9.506 (s,1H), 
8.111(d,2H,J=8.4), 8.051 (d,2H,J=8.4), 7.849(d,1H, J=12.4)，  7.541(d,1H, J=8.8)， 
7.390(t,1H, J=8.8), 3.017(s,3H). 
13
C-NMR (100MHz, DMSO-d6) δ: 164.823, 
157.563,155.130(1C),  138.997, 138.551, 138.448(1C),  132.999(2C), 129.039(2C), 
128.377, 120.792,120.659(1C), 118.723, 116.841,116.810(1C), 114.574, 
108.540,108.289(1C), 56.503. DUIS-MS calculated for C15H12FN3O3S, [M-H]-: 332.05, 
found 332.0,  Purity: 98.8%. 
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Figure 4.53 The Chemical construction of  4-cyano-N-(3- 
fluoro-4-(methylsulfonamido)phenyl)benzamide 
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 N-(3-fluoro-4-(methylsulfonamido)phenyl)-3-(trifluoromethyl)benzamide (48) 
Yield 43.5%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.663(s,1H), 9.504(s,1H), 
8.295(s,1H), 8.281(d,1H,J=8.0), 8.001(d,1H,J=8.0), 7.850(d,1H,J=12.8), 
7.805(d,1H,J=8.0), 7.548(d,1H,J=8.8), 7.396 (d,1H, J=8.8). 3.021(s,3H). 
13
C-NMR 
(100MHz, DMSO-d6) δ:  164.712, 157.592,155.158(1C), 138.634,138.534(1C), 135.882, 
132.364, 130.297, 130.212,129.892,129.573,129.893(q,1C), 
128.444,125.782,123.070,120.360(q,CF3), 128.378, 124.728(m,1C), 123.070, 
120.710,120.579(1C),  116.898,116.867(1C),  108.626,108.377(1C), 40.062. 
DUIS-MS calculated for C15H12F4N2O3S, [M-H]-: 375.04, found 374.9,  Purity: 98.2%.   
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Figure 4.54 The Chemical construction of N-(3-fluoro-4-(methyl 
sulfonamido)phenyl)-3-(trifluoromethyl)benzamide 
 
 4-chloro-N-(3-fluoro-4-(methylsulfonamido)phenyl)-3-nitrobenzamide (49) 
Yield 42.6%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.733(s,1H), 9.521(s,1H), 
8.639(s,1H), 8.266 (d,1H, J=8.4), 7.999(d,1H,J=8.4), 7.830(d,1H,J=12.8), 
7,528(d,1H,J=8.8), 7.404(t,1H,J=8.8, 3.023(s,3H). 
13
C-NMR (100MHz, DMSO-d6) δ:  
163.136, 157.520,155.099(1C), 149.891, 138.312,138.209(1C), 134.965, 133.335, 
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132.516, 128.799, 128.372, 125.352, 120.951,120.922(1C), 116.917,116.556(1C), 
108.640,108.399(1C), 40.063.  DUIS-MS calculated for C14H11ClFN3O5S, [M-H]-: 
386.00, found 385.9; Purity: 96.3%. 
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Figure 4.55 The Chemical construction of 4-chloro-N-(3- 
fluoro-4-(methylsulfonamido)phenyl)-3-nitrobenzamide 
 
 N-(3-fluoro-4-(methylsulfonamido)phenyl)-3,5-bis(trifluoromethyl) benzamide 
(50) 
Yield 41.7%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.845(s,1H)， 9.537(s,1H)， 
8.613(s,2H)，8.400(s,1H)， 7.844(d,1H,J=12.8)， 7.541(d,1H,J=8.8)， 7.423(d,1H, J=8.8)， 
3.031（s,3H） . 13C-NMR (100MHz, DMSO-d6) δ: 163.215, 157.495,155.061(1C), 
138.210,138.109(1C), 137.232, 131.508,131.188,130.856,130.526(q,2C) ， 
129.081(m,2C), 128.270, 127.653,124.933,122.219,119.504(q,2CF3), 125.823(m1C)， 
121.081,120.950(1C)， 117.063,117.035(1C)，108.812,108.561(1C)， 40.059. DUIS-MS 
calculated for C16H11F7N2O3S, [M-H]-: 443.03, found  442.9,  Purity: 97.8%. 
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Figure 4.56 The Chemical construction of N-(3-fluoro-4-(methyl 
sulfonamido)phenyl)-3,5-bis(trifluoromethyl) benzamide 
 
 4-chloro-N-(3-fluoro-4-(ethylsulfonamido)phenyl)benzamide (51) 
Yield 50.2%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.509 (s,1H), 9.506 (s,1H), 
7.986 (d,2H, J=8.4), 7.830(dd,1H, J1= 2.0, J2= 12.8) ,  7.637 (d,2H,J=8.4), 7.518 (d,1H, 
J=8.8), 7.372 (t,1H,J=8.8), 3.078 (q,2H,J=7.2), 1.275 (t,3H,J=7.2).
 13
C-NMR (100MHz, 
DMSO-d6) δ: 165.076, 157.435,155.009(1C),  138.703,138.600(1C), 137.160, 133.676, 
130.133, 129.020, 128.327, 120.455,120.332(1C), 116.735,116.704(1C), 
108.383,108.132(1C), 46.702, 8.478. DUIS-MS calculated for C15H14ClFN2O3S, [M-H]-: 
355.03, found 354.9,  Purity: 97.5%. 
 
O
H
N
S
O
O
N
H
F
Cl
 
Figure 4.57 The Chemical construction of 4-chloro-N-(3- 
fluoro-4-(ethylsulfonamido)phenyl)benzamide 
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 4-cyano-N-(3-fluoro-4-(ethylsulfonamido)phenyl)benzamide  (52) 
Yield 53.2%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.682 (s, 1H), 9.533 (s,1H), 
8.110 (d,2H, J=8.4), 8.049 (d,2H,J=8.4), 7.836(d, 1H, J=12.8), 7.526 (d,2H,J=8.8), 7.391 
(t,1H,J=8.8), 3.084 (q,2H, J=7.2), 1.276 (t,3H,J=7.2) .
 13
C-NMR (100MHz, DMSO-d6) δ:  
164.802, 157.365,154.936(1C), 138.989, 138.393,138.291(1C), 132.995(2C), 
129.038(2C), 128.252, 120.785,120.652(1C), 128.726, 116.835,116.804(1C), 114.563, 
108.482,108.232(1C), 46.724, 8.475. DUIS-MS calculated for C16H14FN3O3S, [M-H]-: 
346.07, found  345.9  Purity: 97.7%. 
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Figure 4.58 The Chemical construction of 4-cyano-N-(3- 
fluoro-4-(ethylsulfonamido)phenyl)benzamide 
 
 N-(3-fluoro-4-(ethylsulfonamido)phenyl)-3-(trifluoromethyl)benzamide (53) 
Yield 52.3%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.662(s,1H), 9.531(s,1H),  
8.292(s,1H), 8.268 (d,1H,J=7.2), 7.997 (d,1H,J=7.2), 7.826(m, 2H), 7.530(d,1H,J=8.0), 
7.397 (d,1H,J=8.0), 3.089(q,2H,J=7.0), 1.281(t,3H,J=7.0). 
13
C-NMR (100MHz, 
DMSO-d6) δ: 164.689, 157.393,154.968(1C),  138.479,138.375(1C), 135.872, 132.357, 
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130.289, 130.211,129.883,129.562,129.242(q,1C), 128.868(m,1C), 128.261, 
124.726(m,1C), 120.708,120.576(1C),  116.886,116.854(1C), 108.565,108.313(1C), 
46.737, 8.490. DUIS-MS calculated for C16H14F4N2O3S, [M-H]-: 389.06,  found 388.9,  
Purity: 97.5%. 
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Figure 4.59 The Chemical construction of N-(3-fluoro-4-(ethyl 
sulfonamido)phenyl)-3-(trifluoromethyl)benzamide 
 
 4-chloro-N-(3-fluoro-4-(ethylsulfonamido)phenyl)-3-nitrobenzamide (54) 
Yield 52.5%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.748(s,1H), 9.546 (s,1H), 
8.642(s,1H), 8.268(dd,1H, J1= 2.0, J2= 8.4) , 7.997 (d,1H,J=8.4), 7.826 (d,1H,J=12.8), 
7.516(dd,1H,J=8.8,2.0), 7.403 (t,1H,J=8.8), 3.089 (q,2H,J=7.3), 1.277 (t, 3H,J=7.3) .
 
13
C-NMR (100MHz, DMSO-d6) δ: 163.116, 157.328,154.999(1C), 147.872, 
138.169,138.071(1C), 134.955, 133.349, 132.502, 128.784, 128.239,128.233(1C),  
125.371, 120.943,120.811(1C), 116.911,116.880(1C),  109.583,109.331(1C),  46.766, 
6.479. DUIS-MS calculated for C15H13ClFN3O5S, [M-H]-: 400.02, found 399.9,  Purity: 
98.8%. 
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Figure 4.60 The Chemical construction of 4-chloro-N- 
(3-fluoro-4-(ethylsulfonamido)phenyl)-3-nitrobenzamide 
 N-(3-fluoro-4-(ethylsulfonamido)phenyl)-3,5-bis(trifluoromethyl)benzamide (55) 
Yield 47.9%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.872 (s,1H), 9.563 (s,1H), 
8.618 (s,2H), 8.400 (s,1H), 7.842 (d,1H,J=12.8), 7.533 (d,1H,J=8.8 ), 7.423 (t, 1H, J=8.8), 
3.099 (q,2H,J=7.2), 1.283 (t,3H,J=7.2).
 13
C-NMR (100MHz, DMSO-d6) δ: 163.197, 
157.304,154.872(1C), 138.070,137.972(1C), 137.220, 
131.506,131.176,130.840,130.539(q,2C), 129.081(m,2C), 128.170, 125.772(m,1C), 
127.645,124.932,122.219,119.504(2CF3), 121.066,120.940(1C),  117.065,117.028(1C), 
108.757,108.504(1C), 46.795, 8.491.  DUIS-MS calculated for C17H13F7N2O3S, [M-H]-: 
457.05,  found  456.9,  Purity: 98.5%. 
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Figure 4.61 The Chemical construction of N-(3-fluoro-4-(ethyl 
sulfonamido)phenyl)-3,5-bis(trifluoromethyl)benzamide 
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 4-chloro-N-(3-fluoro-4-(trifluoromethylsulfonamido)phenyl)benzamide (56) 
Yield 45.6%. 
1
H-NMR (400MHz, DMSO-d6) δ:   16.200(s,1H)，10.587(s,1H), 
7.986 (d,2H, J=8.4), 7.872 (d,1H, J=12.8), 7.639(d,2H,J=8.4), 7.576(d,1H, J=8.4), 
7.391(t,1H,J=8.4). 
13
C-NMR (100MHz, DMSO-d6) δ: 165.260, 159.039,158.573(1C)，
140.280, 140.311,140.132(1C)，  137.260，  133.592，  130.173(2C)，129.042(2C), 
119.343,119.136(1C), 116.821,116.789(1C), 108.320,108.069(1C). DUIS-MS calculated 
for C14H9ClF4N2O3S, [M-H]-: 394.99, found  394.9,  Purity: 97.8%. 
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Figure 4.62 The Chemical construction of 4-chloro-N-(3- 
fluoro-4-(trifluoromethylsulfonamido)phenyl)benzamide 
 
 4-cyano-N-(3-fluoro-4-(trifluoromethylsulfonamido)phenyl)benzamide (57) 
Yield 47.6%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.770(s, 1H), 
8.111(d,2H,J=8.0), 8.055(d,2H,J=8.0), 7.892(d,1H,J=12.8), 7.587(d,1H,J=8.8), 
7.417(t,1H,J=8.8). 
13
C-NMR (100MHz, DMSO-d6) δ: 165.018, 158.667,156.213(1C), 
138.888, 133.163,133.138(1C), 133.012(2C), 130.305, 129.088(2C), 
121.943,121.911(1C)，118.704, 116.933,116.902(1C), 114.657, 108.401,108.154(1C). 
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DUIS-MS calculated for C15H9F4N3O3S, [M-H]-: 386.02, found  385.9  Purity: 97.9%. 
 
O
N
H
S
O
O
H
N
F
F
F
F
N 
Figure 4.63 The Chemical construction of 4-cyano-N-(3- 
fluoro-4-(trifluoromethylsulfonamido)phenyl)benzamide 
 
 N-(3-fluoro-4-(trifluoromethylsulfonamido)phenyl)-3-(trifluoromethyl)benzami
de (58) 
Yield 47.5%. 
1
H-NMR (400MHz, DMSO-d6) δ:  10.776 (s,1H),  8.299 (S,1H),  
8.286 (d,2H, J=7.6), 8.002 (d, 1H, J=7.6), 7.906 (d, 1H, J=12.4), 7.833(t, 1H, J=7.6), 
7.605 (d, 1H, J=8.2), 7.418 (t,1H, J=8.2) . 
13
C-NMR (100MHz, DMSO-d6) δ: 164.897, 
158.680,156.226(1C),  140.421,140.341(1C), 135.781, 132.419, 132.377, 130.296, 
130.265, 130.223,129.902,129.58,1129.260(q,1C), 128.917(m,1C) ， 124.806(m,1C), 
123.059,122.488(1C), 116.989,116.962(1C), 108.499,108.247(1C). DUIS-MS calculated 
for C15H9F7N2O3S, [M-H]-: 429.01,  found  428.9,  Purity: 98.3%. 
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Figure 4.64 The Chemical construction of N-(3-fluoro-4-(trifluoro 
methylsulfonamido)phenyl)-3-(trifluoromethyl)benzamide 
 
 4-chloro-N-(3-fluoro-4-(trifluoromethylsulfonamido)phenyl)-3-nitrobenzamide 
(59) 
Yield 43.5%. 
1
H-NMR (400MHz, DMSO-d6) δ:   10.760(s,1H), 
10.483(s,1H),8.654(s,1H) , 8.279 (dd,1H, J=8.4,1.2), 7.999 (t,1H,J=8.0),  
7.855(d,1H,J=12.8,), 7.612(m,2H).
 13
C-NMR (100MHz, DMSO-d6) δ: 163.342, 
158.672,156.220(1C), 147.883, 140.242,140.139(1C), 134.865, 133.378, 132.536, 
130.371, 128.903, 125.405, 121.886,121.343(1C),  117.010,116.980(1C), 
108.500,108.251(1C).  DUIS-MS calculated for C14H8ClF4N3O5S, [M-H]-: 439.97, 
found 439.8,  Purity:98.1%. 
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Figure 4.65 The Chemical construction of  4-chloro-N- 
(3-fluoro-4-(trifluoromethylsulfonamido)phenyl)-3-nitrobenzamide 
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 N-(3-fluoro-4-(trifluoromethylsulfonamido)phenyl)-3,5-bis(trifluoromethyl)benz
amide (60) 
Yield 40.2%. 
1
H-NMR (400MHz, DMSO-d6) δ: 10.944(s,1H), 8.612(s,2H), 
8.397(s,1H)，7.900(d, 1H, J=12.4),7.594(d, 1H, J=8.6)， 7.448(t, 1H, J=8.6). 13C-NMR 
(100MHz, DMSO-d6) δ: 163.430, 158.665,156.211(1C),  140.171,140.067(1C),  
137.148, 131.525,131.193,130.861,130.531(q,2C), 130.349, 129.150,129.125(3C), 
125.843（m,1C）, 127.629,124.914,122.200,119.486(q,2CF3)，   117.129,117.100(1C), 
108.645,108.396(1C).  DUIS-MS calculated for C16H8F10N2O3S, [M-H]-: 497.00,  
found  497.0,  Purity: 98.2%. 
 
O
NH
F
F
F
F
F
F
S
O
O
HN
F
F
F
F
 
Figure 4.66 The Chemical construction of N-(3-fluoro-4-(trifluoromethyl 
sulfonamido)phenyl)-3,5-bis(trifluoromethyl)benzamide 
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4.4.2.  Biological studies 
 
4.4.2.1. Cell culture.  
Three breast cancer cell lines including SKBR-3, MCF-7, and MDA-MB-231; 
human embryonic kidney cell line HEK293; mice macrophages cell C-38 were obtained 
from ATCC (Rockville, MD). The cells were maintained in RPMI1640 medium 
supplemented with 10% fetal bovine serum (FBS), 2 mmol/L L-Glutamine, 1 mmol/L 
sodium pyruvate, 100 U/mL
 
penicillin-streptomycin. FBS was heat inactivated for 30 min 
in a 56 ºC water bath before use. Cell cultures were grown at 37 ºC, in a humidified 
atmosphere of 5% CO2 in a VWR CO2 incubator (Bridgeport NJ).  
 
 
4.4.2.2. Cell viability analysis 
The effects of the new derivatives on the viability of three breast cancer cell lines were 
assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H- tetrazolium bromide 
assay in four replicates. Cells were grown in RPMI1640 medium in 96-well, flat-bottomed 
plates for 24 h, and were exposed to various concentrations of the compounds dissolved in 
DMSO (DMSO final concentration 0.1%) in media for 48 h. Controls received DMSO 
vehicle at a concentration equal to that in drug-treated cells. The medium was removed, 
replaced by 200 µL of 0.5 mg/ml of 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyl-2H- 
tetrazolium bromide in fresh media, and cells were incubated in the CO2 incubator at 37°C 
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for 2 h. Supernatants were removed from the wells, and the reduced 
3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyl- 2H-tetrazolium bromide dye was solubilized 
in 200 µL/well DMSO. Absorbance at 570 nm was determined on a plate reader. Statistical 
and graphical information was determined using GraphPad Prism software (GraphPad 
Software Incorporated) and Microsoft Excel (Microsoft Corporation). IC50 values were 
determined using nonlinear regression analysis. 
 
 
4.4.2.3. Western blot 
SKBR-3 cells were treated with JCC76 (1µM), compound 16 (0.1, 0.3, 1µM) and 
compound 17 (0.1, 0.3, 1µM) for 48 h. The cells were lysed, briefly sonicated, and 
centrifuged at 12000g 
loading
 
buffer for 5 minutes, electrophoresed on a 10% SDS-polyacrylamide
 
gel, and 
transferred onto polyvinylidene difluoride (PVDF) membrane. The membrane was 
blocked for 1 hour with 5% nonfat milk in PBST and then incubated with specific 
primary antibody (Cell Signaling). After
 
washing, the membrane was incubated
 
with 
horseradish-conjugated secondary antibody (Cell Signaling). The bands were visualized 
by chemiluminescence with ECL reagent (Thermo Scientific). 
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4.4.2.4. Small chaperone activity assay.  
Alpha-crystalline chaperone activity assay: 24 µlmg/ml insulin stock solution was 
added to the single well of 384 well plate, 3µl 5mg/ml alpha-crystalline, 71 µl PBS buffer 
with appropriate concentration of compound dissolved inside were added as well.  The 
mixture was thoroughly mixed and incubated at 37 ºC for 5 min, whereupon 2 µL of 1M 
DTT in water was added to initiate the insulin aggregation. The absorbance (A) at 400 
nm was monitored over 45min using a plate reader. A mixture of insulin in the absence or 
presence of alpha-crystalline with 0.1% DMSO was used as control.  
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CHAPTER V 
CONCLUSION AND FUTURE DIRECTIONS 
 
 
5.1 Conclusion 
Through HSP27 inhibition several client proteins will be downregulated, HER2 is 
one of those client proteins. Inhibiting HSP27 became an indirectly HER2 overexpressed 
breast cancer therapeutic strategy. In previously study we have identified a lead 
compound JCC76 which was generated from COX-2 inhibitor, Nimesulide. The lead 
compound JCC76 exhibit selective inhibition against HER2 overexpressed breast cancer 
cell and inhibit the function of HSP27. 
In the first study totally 23 compounds were synthesized through a five steps 
reaction scheme adapted from JCC76 synthesized scheme. The structure of new analogs 
was confirm by proton and carbon NMR and LC-MS. The purity of products was exam 
by LC-UV set up wavelength at 260nm. Cell viability assay was used to test the analogs 
ability to inhibit cell proliferation. Western-blot and chaperone assay were used to 
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investigate the anti-proliferate cellular mechanism. 
The major structural difference between new analogs and lead compound JCC76 is 
the flipped sulfonamide moiety. The SAR study indicate that in the B moiety 
2,5-dimethoxybenzy group contributes more in cell proliferation inhibition compared to 
2,5-dimethybenzy group. For the B moiety, SAR study suggests that it is critical for the 
compounds’ anti-proliferate activity against SKBR-3 cells, the difference of potency 
between the least potent compound and the most potent one could be 250 folds. Electron 
withdrawing groups on the benzyl amide group harm the biological activity and bulky 
electron donating substitution groups such as iodo, methoxy on benzyl amide moiety 
enhance the compounds’ overall activity. From 23 compounds, two were selected for the 
further studies because of their potency and selectivity. In the chaperone inhibition 
experiment, the selected compounds, 16 and 17, inhibited the protective function of small 
chaperone, α-crystalline, against DTT induced insulin denaturation and aggregation. This 
result indicates that the ligand based structural optimization analogs preserved the 
chaperone inhibition of the lead compound. In the HER2 downregulation experiment, the 
results indicate a dose-dependent downregulation of HER2 for both compounds, 
especially compound 16 at 1 and 0.3μM concentration where at 1μM it showed a 3 fold 
decrease in HER2 compared to JCC76 at same concentration. 
In the second study we try to improve inhibitors’ water solubility and cell uptake by 
decrease molecular size and weight. Totally 60 compounds were synthesized. The 
structure of new analogs were confirm by proton and carbon NMR and LC-MS. The 
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purity of products was detected by LC-UV set up wavelength at 260nm. Cell viability 
assay was used to test the analogs ability to inhibit cell proliferation. 
To improve solubility 2,5-dimethybenzy group was replace by 4 difference small 
function groups, three sulfonamide with small alky chain were choose and 5 benzyl 
amide group which are highly polar and show potent SKBR-3 cell growth inhibition were 
used. Through the combination of these substitution groups 60 compounds were designed. 
The SAR study indicates several compounds with 3-trifluoromethylbenzamide groups 
showed potent and selective inhibition of SKBR-3 cells. However, unexpectedly, some 
analogs showed potent proliferation inhibition against macrophage cells, C38, suggesting 
that these compounds may interfere some unknown critical pathways in macrophage cell. 
 
 
5.2 Future direction 
Through cell viability assay compounds that specifically targeting HER2 
overexpressed breast cancer cell SKBR-3 have been choose. However whether this 
compounds activate by inhibiting HSP27 which destabilize HER2 result in SKBR-3 
proliferate hindrance or not haven’t been confirm. To investigate the mechanism of new 
analogs western-blot and chaperone assay will be used to approve new compounds are 
HSP27 inhibitors 
To further improve HSP27 inhibition, small molecule inhibitor may not be enough. 
A new technology Proteolysis targeting chimera (PROTAC) which can downregulate 
 151 
 
selected protein through increase degradation by ubiquitin-proteasome system. Synthesis 
new compounds using PROTAC may increase HSP27 degradation which result in HER2 
downregulation and more potent inhibition against HER2 overexpressed breast cancer. 
 
 
